



MISSION:

The Ontario College of Pharmacists regulates pharmacy to ensure that the public receives quality services and care.

VISION:

Lead the advancement of pharmacy to optimize health and wellness through patient-centred care.

VALUES:

Transparency - Accountability - Excellence

STRATEGIC DIRECTIONS:

- 1. Optimize the evolving scope of practice of our members for the purpose of achieving positive health outcomes.
- 2. Promote the use and integration of technology and innovation to improve the quality and safety of patient care, and to achieve operational efficiency.
- 3. Foster professional collaboration to achieve coordinated patient-centred care and promote health and wellness.
- 4. Build and enhance relationships with key stakeholders, including the public, the government, our members, and other health care professionals.
- 5. Apply continuous quality improvement and fiscal responsibility in the fulfilment of our mission.

Ontario College of Pharmacists 483 Huron Street Toronto, Ontario M5R 2R4

T 416-962-4861 F 416-847-8200 www.ocpinfo.com

COUNCIL MEMBERS

Elected Council Members are listed below according to District. PM indicates a public member appointed by the Lieutenant-Governor-in-Council. U of T indicates the Dean of the Leslie Dan Faculty of Pharmacy, University of Toronto. U of W indicates the Hallman Director, School of Pharmacy, University of Waterloo.

H Christine Donaldson

H Regis Vaillancourt

K Esmail Merani (Vice President)

(Vice President)

K Mark Scanlon
(President)

L Jillian Grocholsky

L Michael Nashat

I Farid Wassef

M Favez Kos

M Don Organ

M Laura Weyland

N Bonnie Hauser N Christopher Leung

N Ken Potvin

P. Jon MacDonald

P Douglas Stewart

T Michelle Filo TH Goran Petrovic

PM Kathy Al-Zand

PM Linda Bracken

PM Babek Ebrahimzadeh

PM David Hoff

PM Javaid Khan

PM John Laframboise

PM Lewis Lederman

PM Aladdin Mohaghegh

PM Sylvia Moustacalis

PM Shahid Rashdi

PM Joy Sommerfreund U of T Heather Boon

U of W David Edwards

Statutory Committees

- Executive
- Accreditation
- ullet Discipline
- Fitness to Practise
- Inquiries Complaints & Reports
- Patient Relations
- Quality Assurance
- Registration

Standing Committees

Communications

- Drug Preparation Premises
- Elections
- Finance & Audit
- Professional Practice

COLLEGE STAFF

Pharmacy Connection Publisher x 2262, Idecou@ocpinfo.com

Office of the CEO and Registrar x 2241, Itodd@ocpinfo.com

Office of the Deputy Registrar x 2241, ltodd@ocpinfo.com

Office of the Director of Finance and Administration x 2241, ltodd@ocpinfo.com

Pharmacy Practice

x 2236, civan@ocpinfo.com

Registration Programs

x 2250, jsantiago@ocpinfo.com

Structured Practical Training Programs x 2297, vclayton-jones@ocpinfo.com

Investigations and Resolutions x 2219, investigations@ocpinfo.com

Continuing Education Programs and Continuing Competency Programs

x 2264, ckuhn@ocpinfo.com

Pharmacy Openings/Closings, Pharmacy Sales/Relocation ocpclientservices@ocpinfo.com

Registration and Membership Information ocpclientservices@ocpinfo.com

Pharmacy Technician Programs ocpclientservices@ocpinfo.com

Publications

x 2244, rvandoorn@ocpinfo.com

The objectives of Pharmacy Connection are to communicate information about College activities and policies as well as provincial and federal initiatives affecting the profession; to encourage dialogue and discuss issues of interest to pharmacists, pharmacy technicians and applicants; to promote interprofessional collaboration of members with other allied health care professionals; and to communicate our role to members and stakeholders as regulator of the profession in the public interest.

We publish four times a year, in the Fall, Winter, Spring and Summer.

We also invite you to share your comments, suggestions or criticisms by letter to the Editor. Letters considered for reprinting must include the author's name, address and telephone number. The opinions expressed in this publication do not necessarily represent the views or official position of the Ontario College of Pharmacists.

Mark Scanlon, R.Ph., B.Sc.Phm. President

Marshall Moleschi, R.Ph., B.Sc. (Pharm), MHA CEO and Registrar

Anne Resnick, R.Ph., B.Sc.Phm., CAE Deputy Registrar aresnick@ocpinfo.com

Lori DeCou Publisher

ldecou@ocpinfo.com

Agostino Porcellini Production & Design / Webmaster aporcellini@ocpinfo.com

ISSN 1198-354X
© 2015 Ontario College of Pharmacists
Canada Post Agreement #40069798
Undelivered copies should be returned to the
Ontario College of Pharmacists. Not to be
reproduced in whole or in part without the
permission of the Publisher.





CONTENTS

Registrar's Message	4
Council Report	5
Commitment to Transparency	7
CQI Benefits Patients in Community Pharmacies	12
Update: College to Inspect Hospital Pharmacies	16
New Key Initiative on Website: Practice Assessments	18
Factsheet: Advertising	19
One Year Later: OCP Website is a Great Resource for Practitioners	20
Patch 4 Patch Initiative: Fentanyl Abuse Prevention – A Shared Responsibility	22
Coroner's Inquest, Polypharmacy and the Elderly	24
ISMP: An Opioid-Related Death in a Small Community Hospital	31
Respect for Patients on Opioid Agonist Maintenance Treatments (OAMT): No Place for Stigma	36
Discipline Decisions	38
Focus on Error Prevention: Similar Drug Names	43
Structured Practical Training: Now and the Future	44
Thank You Preceptors	44
CE Resources	57



Marshall Moleschi, R.Ph., B.Sc. (Pharm), MHA CEO and Registrar

Maintaining the public's trust in the safe, effective and ethical delivery of pharmacy services by pharmacists and pharmacy technicians is central to our role as regulator for the profession of pharmacy in Ontario – whose mandate is to serve and protect the public interest.

Recent media stories – which have brought to light the importance of the role pharmacy professionals have in assuring medications are safe and appropriate for patients and the potential consequences when standards of practice are not met – are concerning to the College.

Holding pharmacists and pharmacy technicians accountable to the Standards of Practice is not a new expectation or unique to the profession of pharmacy. The Regulated Health Professions Act (RHPA), which governs all healthcare professions in Ontario, includes the requirement for regulatory colleges "to develop, establish and maintain programs and standards of practice to assure the quality of the practice of the profession".

The <u>Standards of Practice for Canadian Pharmacists</u> (March 2009)

Standards of Practice are foundational, not aspirational – a concept that may not be as well understood as it needs to be.

and the Standards of Practice for Canadian Pharmacy Technicians
(November 2011), developed by the National Association of Pharmacy Regulatory Authorities (NAPRA), have been adopted by this College as the Standards governing the practice of pharmacy here in Ontario.

The Standards of Practice, as outlined in the introduction to these documents, are minimum standards that all registered pharmacists and pharmacy technicians must meet. Regardless of a practitioner's position or practice environment, when a pharmacist or pharmacy technician performs a specific role, they must perform it to the level specified in the Standards of Practice and meet all of the standards associated with that role.

The Standards cover all aspects of pharmacy practice including the appropriate provision of Schedule II drugs, which require the professional intervention of pharmacists to determine appropriateness of medication for the patient.

Standards of Practice are foundational, not aspirational — a concept that may not be as well understood as it needs to be.

Collectively, we must do better. Just as the College holds individual practitioners accountable to continuous quality improvement, we also hold ourselves accountable to continuous quality improvement.

An example would be the recent introduction of the new practice assessment process, which will enhance routine pharmacy inspections. In addition to the assessment of pharmacy operations and processes, we are introducing an evaluation of an individual practitioner's performance and are shifting the focus throughout the assessment to an evaluation against practice standards.

With over 1,500 pharmacy visits a year, these new practice assessments provide a significant opportunity for College practice advisors to work directly with pharmacists and pharmacy technicians, in their own practice setting to coach, mentor and share best practices, with a goal of enhancing adherence to the Standards and improving patient health outcomes.

These new practice assessments are just one of the many examples of initiatives that we as a College, and you as individual practitioners, must embrace as a profession committed to a culture of continuous quality improvement.

By design, the Standards of Practice outline how all aspects of pharmacy practice are meant to be delivered to mitigate risk and maximize health outcomes. The College expects – and patients trust – that pharmacists and pharmacy technicians will diligently and conscientiously practice to these Standards each and every day.

DECEMBER 2014 COUNCIL MEETING

As recorded following Council's regularly scheduled meeting held at the College offices on Dec. 8, 2014.

TRANSPARENCY:

RESPONSE TO MINISTER OF HEALTH AND LONG-TERM CARE

On Oct. 4, 2014, Minister Hoskins wrote to all health regulatory College Councils and transitional Councils and asked that each College report to the Ministry (by Dec. 1, 2014) outlining present and future initiatives relating to how the College is embracing transparency and making more information regarding decisions and processes available to the public. This College's response — as well as the Minister's letter — is posted on the College website under Key Initiatives: Commitment to Transparency.

APPROVED AMENDMENTS TO BY-LAWS DEALING WITH INFORMATION ON THE PUBLIC REGISTER

Following consideration of comments received during the 60-day public consultation period (ending Nov. 19, 2014), Council approved amendments to College By-law No. 3 relating to phase one of the Transparency Project — a multi-staged initiative designed to make more relevant information regarding regulatory decisions and processes available to the public.

Specifically, the amended by-law includes the posting of a summary of any findings of guilt – made after April 1, 2015 – against a member in respect of a federal or provincial offence that the College becomes aware of, and that the Registrar believes is relevant to the member's suitability to practise. As well, a change was made to the wording of

the posted summaries of current custody or release conditions in provincial or federal offence processes that the College becomes aware of, and that the Registrar believes are relevant to the member's suitability to practise.

Finally, with respect to discipline hearings regarding professional or proprietary misconduct where the matter is outstanding, the amended by-law allows for the posting on the public register of the notice of hearing, if the hearing is awaiting scheduling a statement of that fact, and if the hearing is completed and awaiting a decision, a statement of that fact.

The approved <u>By-law No. 3</u> is now posted on the College's website.

PROPOSED AMENDMENTS TO BY-LAWS DEALING WITH INFORMATION ON THE PUBLIC REGISTER

Council also passed, for public consultation, additional proposed amendments to By-law No. 3 that will further expand the information made available on the public register about pharmacists and pharmacy technicians.

These amendments are related to phase two of the Transparency Project. A few of the key proposed provisions include: the posting of some complaint outcomes – cautions and specified continuing education or remediation programs (SCERP) resulting from the Investigations, Complaints and Reports Committee (ICRC) process – and any federal or provincial charges against a member that the College becomes aware of, and that the







Registrar believes are relevant to the member's suitability to practise.

The proposed by-law amendments were posted for a 60-day public consultation (deadline Feb. 10, 2015). Feedback received will be considered at the March 2015 Council meeting.

DPRA REGULATIONS – REWRITE PROJECT

Prompted by the pending passage of Bill 21, Safeguarding Health Care Integrity Act, 2014, the regulations under the DPRA (Drug and Pharmacies Regulation Act) need to be redrafted. Council received, for information, the proposed framework for this project, noting that the newly drafted regulations will be performance based, will focus on high risk practices (i.e. those that impact patient and public safety), and will support practice evolution and change. It is anticipated that draft regulations will be brought to the March Council meeting for approval for public consultation.

REGISTRATION REGULATION REQUIREMENTS APPROVED BY COUNCIL

Under the Registration Regulation, there are references to requirements which are to be approved by Council. These requirements are approved through resolutions and allow the College to make changes in these specific areas to keep the regulation current, without having to actually change the regulation.

Three such amendments were approved by Council at this meeting.

- 1. The addition of the University of Toronto PharmD for Pharmacists Program, as an approved bridging program
- 2. The addition of programs that will be considered to have met the requirements of the College's Structured Practical Training (SPT). These programs are:
 - The entry level PharmD program at the Leslie Dan Faculty of Pharmacy at University of Toronto
 - The entry level PharmD program at the School of Pharmacy at the University of Waterloo
 - The PharmD for Pharmacists Program at the University of Toronto

Read more information on <u>registration requirements</u> on the College website.

STRATEGIC PLANNING 2015

Progress continues towards meeting the goals and objectives set out in the Strategic Plan and Council received the progress report of action taken by all College areas since the September 2014 Council meeting. Activities set in March 2012 are expected to reach completion in 2015 when Council will embark upon the development of the next 3-year Strategic Plan. To this end, the College has engaged the services of Dr. Elaine Todres, who has held various roles with the government of Ontario and whose firm specializes in corporate governance and strategy, to facilitate Council's strategic planning session set for March 2015. Re

FUTURE COUNCIL MEETING DATES

- Monday, March 9 and Tuesday, March 10, 2015
- Monday, June 15, 2015
- Thursday, Sept. 17 and Friday, Sept. 18, 2015

For more information respecting Council meetings, please contact Ms. Ushma Rajdev, Council and Executive Liaison at urajdev@ocpinfo.com

Commitment to Transparency


The College is committed to continuously and collaboratively working to identify and implement measures to enhance transparency, and ensure the public has access to the information that they need to make informed choices about their healthcare.


Transparency involves more than just providing timely access to relevant and accurate information about pharmacists, pharmacy technicians and pharmacies. It also requires a clear understanding of regulatory processes and decision–making. Enhancing the public's trust and confidence in the people who provide their care (and the regulatory bodies that govern them) is the underlining objective of transparency.

In 2012, the College – as a member of the Advisory Group of Regulatory Excellence (AGRE) – began work on a collaborative project focused exclusively on examining transparency. Committed to a principled and consistent approach, AGRE – which is made up of representatives from medicine, nursing, dentistry, optometry and physiotherapy – developed transparency principles that are being used extensively by all colleges to guide decision-making.

In June 2014, College Council approved the recommendation from AGRE for a two-phased approach to implement changes for the disclosure of additional information regarding member-specific decisions and regulatory processes. A summary of these can be found on page 10.

MEASUREMENT OF RISK





After approval from Council, the College conducted a 60-day consultation for both phase one (Sept. 19, 2014 to Nov. 19, 2014) and phase two (Dec. 12, 2014 to Feb. 10, 2015) recommendations on our website. The key questions and concerns raised during these consultations are summarized on page 11, with all comments archived at www.ocpinfo.com/about/consultations.

Council, having considered the feedback received during consultation, approved the changes for phase one recommendations at their December 2014 meeting. Council is scheduled to consider phase two recommendations at its March 2015 meeting, following the review of feedback received during the consultation.

Phase two proposed changes include, for the first time, making some information relating to the

outcomes of the College's Inquiries, Complaints and Reports Committee (ICRC) — specifically cautions and education orders called SCERPs (specified continuing education and remediation programs) — available to the public. Currently, only information about matters that the ICRC refers to Discipline is made public.

The College used the "Measurement of Risk" developed by AGRE in determining which additional ICRC outcomes should be made public. This ensures consistency among professions and will ultimately provide the public with access to similar information about each of their healthcare providers.

In developing the "Measurement of Risk", AGRE drew heavily from the transparency principles – in particular Principle 7: the greater the potential risk to the public, the more important transparency becomes. The result is a proposed shift from the public disclosure

TRANSPARENCY PRINCIPLES

PRINCIPLE 1:

The mandate of regulators is public protection and safety. The public needs access to appropriate information in order to trust that this system of self-regulation works effectively.

PRINCIPLE 2:

Providing more information to the public has benefits, including improved patient choice and increased accountability for regulators.

PRINCIPLE 3:

Any information provided should enhance the public's ability to make decisions or hold the regulator accountable. This information needs to be relevant, credible and accurate.

PRINCIPLE 4:

In order for information to be helpful to the public, it must:

- be timely, easy to find and understand.
- include context and explanation.

Phase two proposed changes include, for the first time, making some information relating to the outcomes of the College's Inquiries, Complaints and Reports Committee available to the public.

of only those high risk ICRC outcomes to one that includes moderate risk outcomes as well (see chart at left). Specifically, this would include the disclosure of cautions and SCERPs.

A panel of the ICRC cautions a member when there is significant concern about a member's conduct or practice that could have direct impact on patient care, safety or the public interest if not addressed. Cautions require the member to meet with the ICRC for a face-to-face discussion concerning the member's practice and the changes they have planned that will help avoid similar incidents from occurring in the future. The College would post a summary of the caution on the public register. This would apply to those complaints filed after April 1, 2015, which result in a caution.

A panel of the ICRC issues a SCERP when a serious care or conduct concern is identified and requires a pharmacist or pharmacy technician to upgrade his or her skills. Remediation — monitoring and follow-up — is required when a SCERP is issued. The College would post a summary of the required program on the public register and, as with cautions, this would apply to those complaints filed after April 1, 2015, which result in a caution.

The ICRC also uses risk assessment tools while reviewing matters to help maintain objectivity while striving for consistency in their decisions.

Phase two recommendations also include the proposed disclosure, if known, of criminal charges relevant to the member's suitability to practice and whether a member is currently registered or licensed to practice the profession in another jurisdiction. Both criminal charges and licenses in other jurisdictions are already publicly available from other sources.

Work is also continuing on enhancements to the College's public register to ensure that we are not just making more information available, but that the information that is available is easy to access and clearly understood. Once again, in an effort to provide consistency amongst health professions and to minimize public confusion, AGRE is providing a framework for this work.

Ensuring that Ontarians have access to information that is relevant, timely, useful and accurate – information that evokes public confidence and enhances their ability to make informed choices about their healthcare – will continue to be a priority for this College.

More information regarding transparency can be found in the <u>Key Initiatives</u> section on the College website. **№**

PRINCIPLE 5:

Certain regulatory processes intended to improve competence may lead to better outcomes for the public if they happen confidentially.

PRINCIPLE 6:

Transparency discussions should balance the principles of public protection and accountability, with fairness and privacy.

PRINCIPLE 7:

The greater the potential risk to the public, the more important transparency becomes.

PRINCIPLE 8:

Information available from Colleges about members and processes should be similar.

Summary of approved and proposed by-law changes relating to member-specific information posted on the College's public register

PHASE ONE: CHANGES APPROVED BY COUNCIL AT THEIR DEC. 10, 2014 MEETING

Public consultation was held from Sep. 19, 2014 to Nov. 19, 2014

Posting summarized findings of quilt (if relevant)

The College will post a summary of any federal or provincial findings of guilt – made after April 1, 2015 – against a member if the College knows about them, and the Registrar believes that they are relevant to the member's suitability to practise.

2. Posting of a notice of hearing

The College will post a notice of hearing for any discipline hearing regarding professional or proprietary misconduct where the matter is outstanding. If the hearing is awaiting scheduling, the College will post a statement of that fact. If the hearing is completed and awaiting a decision, the College will post a statement of that fact.

3. Posting of custody or release conditions (if relevant)

A change was made to the wording of the posted summaries of current custody or release conditions in provincial or federal offence processes that the College knows about, and the Registrar believes are relevant to the member's suitability to practise.

PHASE TWO: PROPOSED CHANGES FOR APPROVAL AT COUNCIL'S MARCH 11, 2015 MEETING

Public consultation was held from Dec. 12, 2014 to Feb. 10, 2015

Posting known criminal charges (if relevant)

The College would post a summary of any federal or provincial charges against a member if the College knows about them, and the Registrar believes that they are relevant to the member's suitability to practise.

2. Disclosing members under investigation

The Registrar would confirm that the College is investigating a member if there is a compelling public interest reason to do so pursuant to 36(1)(g) of the Regulated Health Professions Act.

Posting of complaint outcomes: Cautions

The College would disclose when a panel of the Investigations, Complaints and Reports Committee (ICRC) cautions a member as a result of a complaint. The College would post a summary and date of the caution on the public register. This would apply to complaints filed after April 1, 2015.

4. Posting of complaint outcomes: SCERPs

The College would disclose when a panel of the ICRC requires a member to complete a specified continuing education or remediation program (SCERP) as a result of a complaint. The College would post a summary of the required program and its date on the public register. This would apply to complaints filed after April 1, 2015.

Posting of applications for reinstatement

The College would disclose if the Registrar has referred an applicant for reinstatement to the Discipline Committee.

Posting of known licenses in other jurisdictions

The College would disclose whether a member is currently registered or licensed to practice the profession in another jurisdiction, if known.

7. Posting of complaint outcomes: Summary of variation

The College would disclose when a panel of the ICRC was required, after a review, to remove or vary an original outcome of a caution or SCERP. This would include posting the process leading up to the review.

What We Heard During Consultation

The College recently asked for feedback, in two phases, on our By-law No. 3 regarding changes to information we make available on our public register. Phase one of the consultation closed on Nov. 19, 2014 and phase two closed on Feb. 10, 2015. We received and considered comments and questions from both practitioners and members of the general public. Below are some of the common questions that we received.

1. Why are pharmacists being singled out?

Pharmacists are not being singled out. All six regulatory colleges that make up the Advisory Group for Regulatory Excellence (AGRE) – medicine, nursing, dentistry, optometry and physiotherapy – are in the process of implementing similar changes with all other health colleges in Ontario expected to follow.

2. Why is the College making findings of guilt made against a member in respect of a federal or provincial offence public?

Findings of guilt made in provincial and federal Court are already public information but can be difficult for the public to locate. In public polling conducted by AGRE, the public rated information about criminal convictions as important in their consideration when choosing members of their healthcare team.

3. Why is the College making charges made against a member in respect of a federal or provincial offence public?

Only those charges relevant to a member's suitability to practice will be made public. Members of the public can already request access to copies of charges through the court. By posting charges on the public register, the College is removing barriers to information that public polling conducted by AGRE identified as relevant, and allowing the public to determine what information is important in their consideration when choosing members of their healthcare team.

4. It seems like the Registrar will make decisions about what should be on the public register in isolation. Will there be a transparent process for decisions about what will be posted?

When by-laws refer to an action or process that will be undertaken by the "Registrar", the intent is not that

the individual will make the decision in isolation, but rather that there will be a College process for carrying out the action. This process is currently being developed, and will be made public once finalized.


5. Will the College be posting all complaints and investigations?

No. However, if approved by Council at their March 2015 meeting, the College will post outcomes from the Inquiries, Complaints and Reports Committee (ICRC) that result in a caution or a requirement for a practitioner to complete a specified continuing education or remediation program (SCERP). This would apply to complaints filed after April 1, 2015.

The proposed changes also include a provision allowing the College to make public the fact that a member is under investigation if there is a compelling public interest reason to do so.

6. Once information is posted on the public register, will there be a time limit on how long this information stays posted?

No. The current consideration is that given its ongoing relevance to the public, once posted information will remain on the public register. There is a process for a member to request removal of information, and requests are considered on a case-by-case basis.



LEARNING FROM
MEDICATION INCIDENTS
AND NEAR-MISSES
HELPS ENSURE A SAFE
SYSTEM AND IMPROVES
PATIENT OUTCOMES

The College, as outlined in the Standards of Practice (SOP), sets clear expectations for community pharmacies to ensure that medication incidents and near misses – identified in their pharmacy and those shared from external sources – are used to strengthen the safety of the medication delivery system and improve patient outcomes. The application of a defined process for identifying and resolving systemic issues allows pharmacists and pharmacy technicians to share learnings with all staff members and observe that the changes implemented are effective.

Continuous quality improvement (CQI) consists of systematic and continuous actions that lead to measurable improvements in healthcare services and the health status of targeted patient groups.¹ The release of the Institute of Medicine's report "To Erris Human" in 2000 has resulted in increased attention to CQI in healthcare in North America. The report detailed the number of medical errors that occur in the healthcare system each year, and identified the need for increased efforts to create a safer healthcare delivery system.²

To achieve safer care for patients, CQI must focus on systemic improvements and not just the tasks that individual practitioners perform. An organization must understand its own delivery system, and the key processes involved in providing services to patients to make improvements. Change can be affected by influencing either what is done or how it is done (i.e. when,



where, and by whom service is delivered). Using a CQI process that focuses on the patient makes use of all members of the team. Basing decisions on data will help provide safer patient care.

Standards for the profession clearly outline that all pharmacists and pharmacy technicians, regardless of role or practice setting, have a responsibility to manage medication incidents and address unsafe practices. This includes promptly communicating and documenting all medication incidents and near misses with the rest of the staff in the pharmacy. It is the responsibility of the Designated Manager (DM) to ensure that there is an appropriate process in place for this to occur, and that learnings are continuously being identified and applied to improve processes within the pharmacy – with the objective of decreasing future incidents.

The processes for identifying medication incidents and near misses must be multi-pronged and incorporate the use of technology, in addition to the application of professional and clinical judgment. Over-reliance on any single approach causes weakness in the overall process. Technology presents challenges such as alert fatigue, while practitioners are subject to human error. Therefore, both approaches must support one another to provide the safest care to patients.

The College acknowledges the importance of having such systems in place. Medication incident detection (error reporting) and CQI are key focus areas during our pharmacy assessments. Each year the College conducts between 1,500 to 2,000 pharmacy visits through our inspection process. During the visits, College practice advisors review the current processes in place against the requirements in the SOP with the DM and support and educate the DM in meeting those requirements. Additionally, the College provides members with tools and frameworks to system-

atically identify, document and share medication incidents on our website under the Medication Incidents practice tool. Members are encouraged to report medication incidents to appropriate external sources such as the Institute for Safe Medication Practices (ISMP) to support broader learning for the profession. Links to the ISMP website and other resources are also provided on the medication incidents practice tool.

Using the lessons learned from medication incidents and near misses to continuously improve processes to minimize errors and maximize health outcomes plays a big part in improving the quality of care provided in community pharmacies.

One of the many tools that DMs could consider using to implement continuous changes in a systematic fashion and measure outcomes is the Plan Do Study Act (PDSA) framework. The PDSA framework allows for quick implementation of small changes in a successive manner, depending on the frequency of the change being tested. Small changes are implemented, and as data is collected and reviewed, the change idea is refined and a new PDSA cycle is used to implement and monitor the refined changes.

The PDSA tool can be used if pharmacies do not already have a tool and process in place to extract learnings from medication incidents and/or near misses, and to implement changes to mitigate future errors. The tool helps to identify the stages within the pharmacy process that could be contributing to errors, develop possible solutions that will address the problem, document and implement changes, and study the outcomes of the changes to determine if further investigation and changes are required. For example, the PDSA tool could be used to develop and implement solutions for dispensing the incorrect dosage or wrong drug, or if patients are not receiving counselling when required.

PLAN DO STUDY ACT FRAMEWORK

ACT

Plan the next cycle Decide whether the change can be implemented

STUDY

Complete the analysis

of the data

Compare data to

predictions

Summerise what was

PLAN

Define the objective, questions and predictions. Plan to answer the questions (who? what? where? when?)

Plan data collection to answer the questions

1. PLAN³

- Develop specific objectives for change
- Make predictions about what will happen and why (define your beliefs about the processes and operation of your pharmacy)
- Answer questions specifically and include a data collection plan
 - i. Who will be responsible for implementing change and collecting data?
 - ii. What is the change that will be implemented and what data will be collected?
 - iii. When will implementation and data collection begin?
 - iv. Where will implementation occur (i.e. physical location or point in workflow) and where will data be recorded?

DO

Carry out the plan Collect the data Begin analysis of the data

> National Health Service⁴

2. DO

- Carry out the change
- Document the outcomes through data collection and subjective observations (both positive and negative)

3. STUDY

- Review data to see if changes are similar to your predictions
- Discuss what has been learned with all staff

4. ACT

- Depending on results, decide whether to adapt, adopt or abandon change
- Start preparing for the next PDSA R

REFERENCES

- Health Resources and Services Administration U.S.
 Department of Health Human Services. Quality Improvement. Retrieved on Feb. 2, 2015 from http://www.hrsa.gov/quality/toolbox/methodology/qualityimprovement/
- 2. Health Quality Ontario. Quality Improvement Science (2013). Retrieved on Feb. 2, 2015 from http://www.hqontario.ca/Portals/0/Documents/qi/qi-science-primer-en.pdf
- 3. Health Quality Ontario. PDSA: Plan-Do-Study-Act Instruction. Retrieved on Feb. 3, 2015 from http://www.hqontario.ca/portals/0/Documents/qi/rf-document-pdsa-cycles1-en.pdf
- 4. National Health Service. Quality and Service Improvement Tools Plan, Do, Study, Act (PDSA). Retrieved on Feb. 2, 2015 from http://www.institute.nhs.uk/quality_and_service_improvement_tools/quality_and_service_improvement_tools/plan_do_study_act.html

UPDATE

College to inspect hospital pharmacies



The legislation introduced by the Ontario government that will provide the Ontario College of Pharmacists with the authority to license and inspect pharmacies within public and private hospitals has passed third reading in the legislature — the last significant step before it becomes enacted into law.

When proclaimed, Bill 21: Safeguarding Health Care Integrity Act, 2014 will:

- Provide the Ontario College of Pharmacists with the authority to license and inspect pharmacies within public and private hospitals, in the same manner it currently licenses and inspects community pharmacies
- Provide the College with the ability to enforce licensing requirements with regard to hospital pharmacies
- Allow the College to make regulations to establish the requirements and standards for licensing, operation and inspection of hospital pharmacies
- Provide government with the ability to extend the College's oversight to other institutional pharmacy locations in the future, as appropriate


UPDATE ON REGULATIONS

The College is currently drafting the necessary regulations to support Bill 21, which will outline the specifics for the inspection of hospital pharmacies. Council will review the draft regulations at their March 2015 meeting and it is expected that they will be circulated for a 60-day public consultation at that time. Following the consultation, Council will review and consider the feedback and approve the regulations before they are submitted to government for final approval. It is anticipated that regulations will be in place by the end of 2015.

ABOUT THE FIRST INSPECTION

College hospital practice advisors will be visiting all hospital pharmacy sites in Ontario by the end of 2015 to conduct the first round "baseline" inspections. To date, about 30 pharmacies have already undergone their first inspection, with about 230 left to go before the end of the year.

The first visit takes approximately one day. A pre-assessment package is sent to the hospital pharmacy ahead of the visit and some materials must



Meechen Tchen, Pharmacist at Children's Hospital of Eastern Ontario

be completed and returned to the College prior to the assessment. College practice advisors spend the day working with pharmacy staff members, those involved in the medication management system, and the senior team discussing pharmacy processes and procedures, and touring the facility. Focus is on the areas of practice with the greatest risk for patient and public safety.

CANADIAN SOCIETY FOR HOSPITAL PHARMACISTS: PROFESSIONAL PRACTICE CONFERENCE 2015

This year OCP attended the annual CSHP Professional Practice Conference held Jan. 31 to Feb. 4, 2015 at the Sheraton Centre Hotel in Toronto. College representatives spoke with hospital pharmacists and pharmacy technicians from across the province about the importance of practicing to the standards, their professional responsibilities and what to expect when the College visits for a hospital pharmacy's first inspection.

If any problems in the pharmacy or medication management system are identified, the practice advisor works with the team to mentor and coach them on how to rectify the problems as soon as possible. The outcomes of these initial baseline assessment visits will be made public once the College has officially received the necessary authority.

FOR MORE INFORMATION

Visit the Key Initiatives section on the College website to learn more about hospital pharmacy inspections. http://www.ocpinfo.com/about/key-initiatives/hospital-oversight/

NEW KEY INITIATIVE ON WEBSITE:

Practice Assessments


As the regulatory body for the profession of pharmacy in Ontario, the College is actively involved in initiatives that further support our mandate of protecting the public by ensuring the safe, effective and ethical delivery of pharmacy services.

To bring greater attention to these important topics – which all pharmacists and pharmacy technicians should familiarize themselves with – the College has created a section on the website titled Key Initiatives. This section, arranged by topic, includes a general overview of the initiative and provides regular updates and links to relevant resources.

The newest key initiative on the website is about the Practice Assessments – the College's new approach to pharmacy inspections.

As part of our commitment to continuous quality improvement, enhancements have been made to the routine pharmacy inspection process. These visits will now include both an assessment of a pharmacy's operations and processes, and an evaluation of an individual practitioner's performance in their practice site

The College is currently piloting the new practice assessment model across the province, and anticipates an official launch in spring/summer 2015.



There are currently four key initiatives available on the website:

- College Oversight of Hospital Pharmacies
- 2. Commitment to Transparency
- 3. Practice Assessments
- 4. Professional Responsibility in Practice

ADVERTISING

Factsheet: Advertising

Published: December 2014

Legislative References: DPRA O. Reg. 58/11, s. 46-48, DPRA O. Reg 58/11, Part IX, s. 49-53, Pharmacy Act O. Reg. 202/94, Part VII.2, s. 28, Pharmacy Act O. Reg. 681/93, Ontario Drug Benefit Act, RSO 1990, c 0.10, Drug Interchangeability and Dispensing Fee Act, RSO 1990, c P.23, Controlled Drugs and Substances Act

Additional References: Professional Responsibility Principles (Pharmacy Connection Spring 2014), Professionalism and Ethical Decision-Making (Pharmacy Connection Spring 2014), The Language of Regulation (Pharmacy Connection Winter 2014)

College Contact: Professional Practice

ADVERTISING - MEMBER'S RESPONSIBILITY:

It is the responsibility of individual members to determine the appropriateness of advertising based on legislative requirements and professional responsibilities. Advertising is addressed through regulations under the Drug and Pharmacies Regulation Act (O. reg. 58/11 Part VIII) and the Pharmacy Act (O. reg. 202/94 Part VII.2). In addition, the College has published multiple resources that a member can utilize to guide ethical and professional decision making. The Ontario College of Pharmacists cannot provide legal advice or make a determination as to whether an ad or sign is in violation of legislative requirements or professional responsibilities. The guidance provided in this fact sheet is not exhaustive and members who, after having read the information provided in the fact sheet, remain unsure about their particular circumstance, should exercise due diligence and obtain independent legal advice to address their outstanding concerns. The College has provided the following resources which a member can utilize to guide decision making with respect to advertising:

LEGISLATION TO CONSIDER WHEN DEVELOPING ADVERTISING

- The portion of the <u>Drug and Pharmacies Regulation</u> <u>Act</u>, O. Reg. 58/11 that refers to Advertising is PART VIII (ADVERTISING), s. 46 to 48
- The portion of the <u>Pharmacy Act</u>, O. Reg. 202/94 that refers to Advertising is Part VII.2 (ADVERTISING), s. 28 TO 30
- The relevant components of the <u>Professional Misconduct Regulations</u>, O. Reg. 681/93,

- The relevant components on the <u>Proprietary Misconduct/Conflict of Interest Regulations</u>, O. Reg. 58/11, Part IX
- Advertising of narcotics is not permitted as per the <u>Narcotic Control Regulations</u> made under the Controlled Drugs and Substances Act, s.70

PROFESSIONAL RESPONSIBILITIES TO CONSIDER WHEN ADVERTISING:

- A member should review the <u>Standards of Practice</u> which demonstrate professional expectations when delivering pharmacy services
- Reviewing the <u>Code of Ethics</u> will provide a member with foundational principles of acceptable conduct that form a framework for ethics and professionalism for the delivery of pharmacy services
- A member must consider the <u>Professional Responsibility Principles</u> to ensure ethical delivery of pharmacy services
- A member must also consider <u>professionalism and</u> ethical decision making
- If considering advertising inducements a member may wish to consult the College's Loyalty Points Policy
- Lastly, the <u>information published to support a</u> <u>member when interpreting legislation</u> should be reviewed

One Year Later: OCP Website is a Great Resource for Practitioners

It's been one year since the College launched our new website and since then we've had thousands of visitors and heard tons of great feedback.

Did you know there are many great resources for practitioners available on the website?

Whether you're working in a community or hospital pharmacy, a corporate or industry environment, or are a student studying for the jurisprudence exam – our website has important information for you.

If you haven't already, check out the member homepage for quick and easy access to information you'll surely find useful.

Here are some highlights:

PRACTICE TOOLS


This special feature on the website brings together information about a number of different practice issues in one central location. Visitors can select a topic from the list and then quickly access any relevant articles, fact sheets, links to some regulations, FAQs, and more.

Current Practice Tool topics:

- Administering Injections
- Compounding
- Designated Managers
- Drug Preparation Premises
- Expanded Scope
- Infection Control
- Interprofessional Collaboration & Teamwork
- Medication Incidents
- Methadone & Buprenorphine
- Narcotics
- Patient Relationships
- Pharmacy Technicians
- Prescription Information and Labelling




- Professional Fees
- Record Keeping, Scanning and Documentation
- Remote Dispensing & Pharmacies Operating Internet Sites
- Standards for Accreditation & Operation



PUBLIC CONSULTATIONS


The College often requests input from members of the profession, the public and other stakeholders regarding new and revised by-laws, regulations, policies and other documents related to pharmacy practice. Information about current and closed consultations is posted at http://www.ocpinfo.com/ about/consultations/.



LOGIN TO MY ACCOUNT

Get quick access to your account or learning (CPD Portal) through the "Login to My Account" button on the top of every page.

Tell us what you think about the website.
Email communications@ocpinfo.com and share your thoughts!



PATCH 4 PATCH INITIATIVE

Fentanyl Abuse Prevention – A Shared Responsibility

The Ontario Association of Chiefs of Police is leading a program to help limit the abuse of fentanyl patches across the province. The misuse of fentanyl is having a devastating effect in many communities. The *Patch 4 Patch* program aims to limit the availability of fentanyl patches and avoid unnecessary deaths.

The inappropriate use, abuse, diversion, storage, and disposal of prescription narcotics and other controlled substances is a public health and safety issue. Communities across Canada have seen a rise in deaths due to the misuse of fentanyl. In Ontario alone there were at least 103 deaths in 2013.

Patch 4 Patch is a collaborative effort between physicians, pharmacists, and patients to promote the safe, effective and responsible use of fentanyl patches. In general, it applies a "one in, one out" model, where patients are asked to return any patches previously dispensed to them back to the pharmacy before they are able to receive more. Patch 4 Patch promotes safety for patients and the community. In returning these patches, patients are contributing to reducing harm as a used patch poses many dangers to children and pets, and contains enough medication to be harmful or fatal to someone who is not prescribed the medication.

Pharmacists are encouraged to consider working together with physicians and patients to implement the *Patch 4 Patch* program where appropriate.

BACKGROUND

Fentanyl is an extremely potent synthetic opioid prescribed for the treatment of chronic pain, usually in patients already tolerant to high doses of less powerful opioids such as morphine or oxycodone. Fentanyl is approximately 100 times more potent than morphine and 40 times more potent than heroin. Fentanyl used for non-medical purposes is most commonly encountered in the form of diverted prescription patches. According to statistics from the Office of the Chief Coroner, deaths attributed to fentanyl in Ontario doubled between 2008 and 2012 from 45 to 116. During this time frame, only oxycodone - which is far more widespread – was connected to more deaths. Fentanyl is sold under the prescription names Duragesic® Mat, Apo-Fentanyl Matrix, Ran-Fentanyl Matrix Patch, Co Fentanyl, PMS-Fentanyl MTX and others.

NON-MEDICAL USE (OR ILLICIT USE)

Fentanyl is known by several street names: Apache, China Girl, China White, Dance Fever, Friend, Goodfella, Jackpot, Murder 8, TNT and Tango and Cash. Aside from using patches in a prescribed manner, users will extract the gel from patches and eat, smoke, inject and dissolve it under their tongues. Because fentanyl is highly soluble, users

Pharmacists are encouraged to consider working together with physicians and patients to implement the *Patch 4*



Fentanyl

will soak pieces of the patch in alcohol and then infuse herbs such as basil with the mixture to smoke. Since the patch is made for a 72-hour slow release, scraping off the medication and smoking or sucking the drug out of the patch can make a single patch lethal. Even patches that are properly used may retain 60 to 80 per cent of the original dosage. A single patch can sell for between \$150 and \$220 in central Ontario, and as much as \$500 in some First Nations communities in northern Ontario.

LEARN MORE

The Ontario College of Pharmacists and College of Physicians and Surgeons of Ontario (CPSO) both support initiatives that curb opioid abuse, including participation in the *Patch 4 Patch* program. The CPSO recently published an article in their magazine, Dialogue, sharing information about fentanyl overdoses and the *Patch 4 Patch* program.

Learn more about the program from the document <u>Patch 4 Patch Initiative</u>: <u>Fentanyl Abuse Prevention – A Shared Responsibility</u> published by the Ontario Association of Chiefs of Police. The document was developed with input from a number of community partners, including the Ontario College of Pharmacists, the College of Physicians and Surgeons of Ontario, and the Ministry of Health and Long-Term Care.

■


ATTENTION: NARCOTICS MANAGEMENT & SECURITY

 Pharmacists are responsible for the management and security of all narcotics in their pharmacy or otherwise under their control

Fentanyl MTX Patch

100 mcg/h

- The most common way to gain illegal access to narcotics or controlled substances is through the use of legitimate prescriptions and forgeries
- Pharmacists are reminded about two fact sheets developed by the College that are intended to reinforce the diligence expected of pharmacists and pharmacy technicians in reducing the number of forged prescriptions that are filled
 - Identifying Forgeries and Fradualent
 Prescriptions
 - Narcotic Reporting of Forgeries and Losses
- Notices from the Ontario Public Drug Programs titled "Prescription Forgery" and alerts generated by the Narcotics Monitoring System are crucial pieces of information that should be made available and used within pharmacies



INQUEST INTO DEATH OF AN ELDERLY PATIENT ON FENTANYL

A 95 year old woman, TP, the subject of a coroner's inquest, died a year after being placed in a retirement home. The reported cause of death was acute myocardial infarction, secondary to coronary artery disease and a left hip fracture, with dementia reported as a contributor.

Documentation irregularities and concern about the use of fentanyl for pain control led the coroner's jury to refer the case for review to the Geriatric and Long-Term Care Review Committee (GLTCRC). The Committee's review and its recommendations to several institutions, in the areas of appropriate pain assessment, evaluation and titration of opioid pain medications, documentation and falls prevention as well as education of healthcare professionals on medication use in the elderly are summarized in Appendix B.

CASE HISTORY:

Apart from documentation irregularities, this case highlights areas where a frail elderly patient on multiple medications was exposed to avoidable risks, with several missed opportunities for timely intervention and optimization of health outcomes.

On admission to the retirement home in April 2011, TP, observed to be in no overt distress, had several documented co-morbid conditions, including chronic kidney disease, hypothyroidism, osteoarthritis, diverticulitis, controlled hypertension, recent TIA and remote history of stroke. Medications in TP's chart that month and updated at various time points, documented as medication reviews, are listed in Appendix A. An initial physiotherapist visit on April 11 identified the patient to be at high risk of falls and a management plan was outlined. A later note, but dated April 4, recorded the finding of two fentanyl patches on the patient.

Over the next few months, TP began to exhibit signs of confusion and a tendency to fall. In May, she had a temporary episode of day/night reversal and a hand injury when going to the bathroom. In September, she suffered a few broken ribs from a fall in the bathroom. Pain from the fall led to an increase in dosage of acetaminophen (now scheduled) and a doubling of her fentanyl patch to 50 mcg every three days. A medication review at this time failed to capture the doubled dose of fentanyl. TP's confusion increased and a week later her fentanyl dose was reduced back to 25 mcg. In November, TP fell and sustained a head injury. That month, episodes of increased blood pressure and angina culminated in two emergency room visits and the prescribing of nitroglycerin patch, after which no further angina was recorded. TP suffered another episode of day/night reversal in January 2012 and three falls during February and March 2012, after which a medication review was recorded. Her family, concerned that TP's pain medication was resulting in confusion, asked that a different doctor assume her care. TP had another fall that month, the fourth in the span of six weeks. This resulted in a hip fracture necessitating surgery. In April 2012, three weeks post-op, TP died of a myocardial infarction.

This is another example where the Principles of Professional Practice (http://www.ocpinfo.com/about/key-initiatives/prof-respon/) should draw attention to an especially vulnerable population.

POLYPHARMACY AND THE ELDERLY

While some elderly adults remain fit and active as they age, many are assailed by complex chronic health conditions. This makes them prey to polypharmacy, defined as taking five or more medications.

- In Canada, a 2009 nationwide population survey reported polypharmacy in over 50 per cent of seniors in institutions and 13 per cent of those at home¹.
- A 2012 report by the Canadian Institute of Health Information (CIHI) cites 66 per cent of Canadian seniors with claims for five or more drug classes, and close to 40 per cent of seniors over the age of 85 with claims for 10 or more drug classes². These figures do not take into account any additional over-the-counter medications.

These statistics give rise to concern because the well known risks of polypharmacy are heightened in the elderly³:

- Age-related physiologic changes influence the metabolism and response to medications
 - Many medications therefore have increased potential for harm in the elderly and are considered inappropriate.
- Presence of complex co-morbid conditions, requiring the use of multiple medications, increases risks of
 - Drug interactions and adverse effects
 - Non-adherence due to complex and multiple drug regimens
 - Prescribing cascades to treat adverse effects of an existing medication
 - o Impaired function and cognition in older adults.

Efficacy and safety of medications is not always well established in older patients

 Despite being the largest consumers of medications, older patients are often underrepresented or excluded from drug efficacy trials.

The consequences of polypharmacy in the elderly, in addition to adverse drug effects and impact on function and cognition, include increased risk of falls, poorer health quality of life, hospitalizations and death⁴. Between 20 per cent and 30 per cent of adults over the age of 65 fall each year from multiple and often avoidable causes. A strong association with fall risk has been observed when certain medications such as antidepressants, antipsychotics, benzodiazepines or those that cause drowsiness, dizziness, hypotension, ataxia and visual impairment are included in the polypharmacy mix.⁵

Lists and criteria for potentially inappropriate medications (PIMs) in the elderly, i.e., medications where actual or potential harms outweigh the benefits, have been developed for clinician reference by expert panels and include the updated Beers criteria^{6,7}, the STOPP criteria⁸ and the Anticholinergic Burden Scale⁹. Indiscriminate prescribing of PIMs, however, continues to be reported. In 2012, CIHI reported more than a third of Canadian seniors using a PIM as identified by the Beers Criteria². Internationally, the results of a systematic review suggest one in five prescriptions for community dwelling older patients are inappropriate¹⁰. This does not include medications or herbals bought without a prescription, many of which could be inappropriate in themselves or have dangerous interactions with other prescribed medications.

MITIGATING RISKS OF POLYPHARMACY

One way to mitigate the risks of polypharmacy and PIMs is by 'deprescribing', a term gaining increasing prominence, and the subject of current research. It involves assessing the benefits and risks of medications, followed by a process of tapering, stopping or withdrawing medications that are not required or that have potentially harmful consequences for the individual patient.¹¹

Available evidence indicates that medications may be withdrawn successfully with little or no harm to the patient¹¹.

- Benefits shown from cohort and observational studies include improved patient health outcomes from resolution of adverse drug events when specific medication classes are withdrawn.¹²
 - Studies have generally been of insufficient duration to determine long-term clinically significant benefits such as reduced hospitalization or improved functionality. Some trials, however, have demonstrated reduced fall risk.
- **Risks** of stopping medications include the potential for adverse drug withdrawal reactions, pharmacokinetic and pharmacodynamic changes and return of the medical condition.
 - Risks can be mitigated with appropriate tapering, monitoring after withdrawal and reinstating the medication if the condition returns.¹²
- Barriers¹³ to stopping a medication that has been prescribed over months or years is complicated by many factors, including but not limited to
 - Patient reluctance and physician inertia, due to fear of unknown negative consequences of discontinuing medications
 - o Lack of insight on harms of PIMs
 - Lack of sufficient data on methods to safely discontinue medications, resulting in clinicians having to rely on their experience and clinical judgement when attempting to taper or stop medications.

Empowering clinicians with evidence based guidance to safely and effectively discontinue inappropriate medications is the subject of current research:

 The Ontario Pharmacist Research Collaboration (OPEN)¹⁴, with its team of experts, led by pharmacist and scientist Dr. Barbara Farrell and scientist James Conklin, has been awarded a three year grant by the Ministry of Health & Long-Term Care in 2013 to develop deprescribing guidelines for the elderly.¹⁵ Reeves et al¹² have proposed a patient-centred deprescribing process, utilizing a five-step cycle that includes a comprehensive medication history, identifying PIMs, assessing if any PIM can be discontinued, planning the withdrawal process – e.g., tapering, and providing monitoring support and appropriate documentation.

ROLE OF PHARMACIST

Pharmacists can play an important role as part of the circle of care for the elderly. As medication experts, and ranking amongst the most approachable and accessible of healthcare providers in Canada, pharmacists are in a position to positively impact the health outcomes of their patients, including the especially vulnerable senior population.

Focusing on the individual patient's needs is pivotal, guided by evidence and with direct input from the patient/caregiver. The acronym MINDFUL below sets out a common-sense approach enabling the pharmacist to optimize the health outcomes of their senior patients^{3,11,12}:

Medical History (M)

- Review the patient's medical and medication history:
 - Ask about prescribed and non-prescribed (overthe-counter) medications, including herbals and vitamins.
 - Ask about changes to health status and medications at every visit.
- Match medication therapy to the patient's condition, age and goals.
- Assess appropriateness of each medication by considering
 - Patient-specific co-morbid conditions, age, renal and liver function
 - The need for existing or new medications e.g., for a palliative care patient with a short life expectancy, prescribing a prophylactic medication that requires several years to realize a benefit may not be considered appropriate.

Identify PIMs (I)

- Use evidence to identify medications that have significant interactions, are unnecessary, constitute duplication of therapy, PIMs, as well as conditions not receiving optimal treatment
- Assess benefits vs risks of continuing or stopping PIM in that individual patient.

Negate PIMs (N)

- Use available evidence and patient-specific criteria to determine the process for safely discontinuing PIM (e.g., taper if in doubt)
- Obtain patient consent and contact the prescriber to provide the recommendation and rationale and effect the change.
- Document the decision and rationale (D)
- Follow up with the patient (F)
 - Monitor the outcome of the change and provide education and support.
- Understanding (U)
 - Elicit patient understanding of the changes and information provided to ensure medications are taken as indicated.

• List all current medications (with any changes) (L)

- Provide an updated medication list for the patient to carry
- Inform all relevant healthcare practitioners in the patient's circle of care of medication changes.

Deprescribing guidelines such as those by the OPEN group, once published, will enhance the ability of clinicians to more confidently reduce medications that are inappropriate or no longer necessary for older patients, thus helping to decrease risks of adverse drug effects and optimize health related quality of life. It is hoped that such guidelines will translate ultimately into a cultural shift in healthcare where reassessing medications as people age becomes part of routine care. 11.14.15

REFERENCES

- Ramage-Morin, PL. Medication use among senior Canadians. Health Matters. March, 2009 Statistics Canada, Catalogue no. 82-003-XPE • Health Reports, Vol. 20, no. 1, March 2009. Accessed November 2014 at http://www.statcan.gc.ca/pub/82-003-x/2009001/article/10801-eng.pdf
- Canadian Institute for Health Information. Drug Use Among Seniors on Public Drug Programs in Canada, 2012 (Ottawa, Ont.: CIHI, 2014). Accessed December 2014 at https://secure. cihi.ca/free_products/Drug_Use_in_Seniors_on_Public_Drug_ Programs EN_web_Oct.pdf
- 3. UpToDate. Drug prescribing for older adults. Accessed December 2014 at http://www.uptodate.com/contents/drug-prescribing-for-older-adults?source=search_result&search=el derly&selectedTitle=2%7E150b
- Fried TR, O'Leary J, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014 Dec;62(12):2261-72
- Seniors falls in Canada. Second report. Public Health Agency of Canada 2014. Accessed online at http://www.phac-aspc.gc.ca/ seniors-aines/publications/public/injury-blessure/seniors_fallschutes_aines/assets/pdf/seniors_falls-chutes_aines-eng.pdf
- Campanelli CM. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. Am Geriatr Soc. 2012 April; 60(4): 616–631. Accessed online at http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3571677/
- 7. AGS Beers Criteria for Potentially Inappropriate Medication Use in Older patients. From the Amrican Geriatric Society. Accessed online at http://www.americangeriatrics.org/files/documents/beers/PrintableBeersPocketCard.pdf
- 8. Gallagher P, O'Mahoney D. STOPP (Screening Tool of Older

- Persons' potentially inappropriate Prescriptions):application to acutely ill elderly patients and comparison with Beers' criteria. Age and Ageing 2008; 37: 673–679. Accessed online at http://ageing.oxfordjournals.org/content/37/6/673.full.pdf+html
- 9. Anon. ABC Anticholinergic Burden Scale. Helping physicians do no harm. Available online at http://www.agingbraincare.org/tools/abc-anticholinergic-cognitive-burden-scale/
- Opondo D, Eslami S, Visscher S, et al. Inappropriateness of Medication Prescriptions to Elderly Patients in the Primary Care Setting: A Systematic Review. PLoS ONE 2012: 7(8):e43617. Accessed online at http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3425478/
- 11. Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013 May;66(3):201-2. Accessed online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694945/pdf/cjhp-66-201.pdf
- 12. Reeve E, Shakib S, Hendrix I et al. The benefits and harms of deprescribing. Med J Aust. 2014 Oct 6;201(7):386-9.
- 13. Anderson K, Stowasser D, Freeman C et al. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014;4:e006544. doi:10.1136/bmjopen-2014-006544. Accessed online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265124/#R20
- 14. Ontario Pharmacist Research Collaboration (OPEN).

 Deprescribing guidelines for the elderly. Accessed online at http://www.open-pharmacy-research.ca/research-projects/emerging-services/deprescribing-guidelines
- Cross C. Introducing deprescribing into culture of medication.
 CMAJ. 2013 Sep 17;185(13):E606.Accessed online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778460/

APPENDIX A. TP'S MEDICATIONS

documented as a 'six month review')	Sept. 14, 2011 (documented as a 'six month review')	March 14, 2012 Medication review
Scheduled:	Scheduled:	Scheduled:
Pentanyl patch 25 mcg q3days Metoprolol 25 mg bid Clopidogrel 75 mg daily Rabeprazole 10 mg daily Venlafaxine XR 75 mg daily Levothyroxine 112 mcg daily Tiotropium inhaler daily	 Fentanyl patch 25 mcg q3days Metoprolol 25 mg bid Clopidogrel 75 mg daily Rabeprazole 20 mg daily Venlafaxine XR 75 mg daily Levothyroxine 0.125 mg daily Spiriva inhaler daily 	 Fentanyl patch 25 mcg q3days Metoprolol 25 mg bid Clopidogrel 75 mg daily Rabeprazole 20 mg daily Venlafaxine XR 75 mg daily Levothyroxine 125 mcg daily Tiotropium inhaler daily
PRN: Salbutamol inhaler Nitrospray	 Spiriva inhaler daily Acetaminophen 650 qid Alendronate 70 mg every Wednesday Candesartan 16 mg/HCT 12.5 mg daily Docusate 100 mg tid Domperidone 10 mg tid ac Ferrous gluconate 300 mg daily Lorazepam 1 mg at bedtime PRN: Nitroglycerin spray Salbutamol inhaler Medical directive for Acetaminophen Diphenhydramine Dimenhydrinate Milk of magnesia Magnesium hydroxide/ aluminium hydroxide Fleet enema Glycerin Guiafenesin Loperamide Lactulose Sennosides 	 Tiotropium inhaler daily Acetaminophen 650 qid Alendronate 70 mg every Wednesday Candesartan 16 mg/HCT 12.5 mg daily Docusate100 mg tid Domperidone 10 mg tid ac Ferrous gluconate 300 mg daily Lorazepam 1 mg at bedtime Nitroglycerin patch 0.2mg/ hr PRN: Salbutamol inhaler Medical directive for Acetaminophen Diphenhydramine Dimenhydrinate Milk of magnesia Magnesium hydroxide/ aluminium hydroxide Fleet enema Glycerin Guiafenesin Loperamide Lactulose Sennosides
) () () () () () () () () () (cheduled: Fentanyl patch 25 mcg q3days Metoprolol 25 mg bid Clopidogrel 75 mg daily Rabeprazole 10 mg daily Venlafaxine XR 75 mg daily Levothyroxine 112 mcg daily Tiotropium inhaler daily RN: Salbutamol inhaler	Scheduled: Fentanyl patch 25 mcg q3days Metoprolol 25 mg bid Clopidogrel 75 mg daily Rabeprazole 10 mg daily Venlafaxine XR 75 mg daily Levothyroxine 112 mcg daily Tiotropium inhaler daily RN: Salbutamol inhaler Nitrospray Ferrous gluconate 300 mg daily Domperidone 10 mg tid ac Ferrous gluconate 300 mg daily Lorazepam 1 mg at bedtime PRN: Nitroglycerin spray Salbutamol inhaler Nitroglycerin spray Medical directive for Acetaminophen Diphenhydramine Dimenhydrinate Milk of magnesia Magnesium hydroxide Aleet enema Glycerin Guiafenesin Loperamide Lactulose

APPENDIX B. GLTCRC REVIEW

Issue	Review	Recommendations	
Documentation	Difficulties in interpreting and analyzing medical and nursing notes: - inconsistent charting methods - notes in English or French - notes written out of order, not labeled as 'late entry' - difficulty reading medication administration sheets in both electronic and printed formats.	To the Retirement Home: - Conduct a review of documentation policies - Focus on standardizing how dates are written - Ensure notes are dated correctly with late entries recorded as such. - Records selected for photocopy or scan should be legible.	
Pain Management	- No formal assessment conducted on the cause, type, location, severity of pain, nor of the appropriateness of pain medications, on admission or on subsequent fall-related increase in pain - Inappropriate doubling of fentanyl patch for new acute pain caused by rib fractures, leading to worsening cognition in TP - Family's concerns for TP's cognition and narcotic use could have been addressed, for example, by reviewing and discontinuing the fentanyl patch, and titrating a shorter acting narcotic to determine an optimal opioid dose to balance pain relief and cognitive function.	1. To Ontario Ministry of Health and Long-Term Care (MOHLTC) and Ontario Association of Long-Term Care Physicians: Reminders to healthcare providers that - falls prevention in any seniors' facility requires an inter-professional approach, and the physician is an important part of that approach. Falls should prompt a review. - while narcotics for musculoskeletal pain in the elderly may be indicated, appropriate use requires: • Accurate diagnosis and description of pain	
Falls Prevention	 Despite the physiotherapist's note indicating TP to be at high risk of falls, and despite ensuing multiple falls, there was no evidence of review by the attending physician of potential medical or medication-related causes for falls. Multiple medications, associated with increased risk of falls in the elderly, were prescribed for TP, including lorazepam, venlafaxine, metoprolol, nitroglycerin and narcotics. 	 Frequent re-evaluation and appropriate titration Use of short acting opiates for treatment of acute musculoskeletal pain Description of goals of therapy e.g., mobility To MOHLTC, Ontario Association of Long-Term Care Physicians, College of Physicians and Surgeons, Ontario College of Family Physicians, Ontario College of Pharmacists and medical schools in Ontario: Education directed to the appropriate health professionals regarding drug therapy for the elderly should be a national priority at all levels: undergraduate, graduate, and continuing education. 	
Bowel regimen	 A PRN bowel regimen is insufficient to prevent serious constipation in an elderly patient on narcotics. The nausea for which domperidone was prescribed might have been secondary to inadequately managed constipation. Occasional diarrhea in this case may have been caused by overflow and the directive to use loperamide was inappropriate. 		
Anticholinergic load	Despite cognitive impairment, TP was prescribed dimenhydrinate and diphenhydramine, medications with known anticholinergic effects. Anticholinergics have the propensity for severe adverse effects including confusion, constipation, dizziness and falls and are considered potentially inappropriate in the elderly.		

ISMP CANADA SAFETY BULLETIN

An Opioid-Related Death in a Small Community Hospital



Pain management is a complex process that can involve a number of pharmacologic treatment modalities, including traditional pain medications (e.g., non-opioids and opioids) and adjunctive pharmacotherapy (e.g., anticonvulsants, antidepressants). Choosing an appropriate starting dose for an opioid, titrating opioid doses, using more than one opioid, and converting from one opioid to another are all elements of pain management wherein errors can lead to significant harm. This bulletin shares findings and recommendations from an ISMP Canada review of an unexpected death that occurred after admission to a small community hospital for management of acute pain. The system vulnerabilities identified during this analysis likely exist in other facilities, and all those affected by this case sincerely hope that the learning shared here will lead to system improvements in hospitals across Canada.

INCIDENT DESCRIPTION

A woman was admitted to hospital for management of pain. Five years earlier, she had undergone back surgery for chronic pain, and her condition was reported to have improved until an injury occurred about 2 months before the hospital admission. According to available prescription records, opioid medication had been prescribed for previous injuries, and it was believed that the patient was taking about 4 tablets of an oxycodone—acetaminophen combination tablet daily before this most recent injury. The combination tablet had been taken more frequently subsequent to the injury, and hydromorphone in both immediate—release (IR) and controlled—release (CR) formulations had also been trialled to address the patient's uncontrolled pain.

The most recent prescriptions, written and dispensed 1 week before the admission, were for CR oxycodone and IR hydromorphone. However, at the time of admission, the patient described use of CR oxycodone only. Opioid usage for the week before admission is detailed in Figure 1. Other medications being taken just before

admission included metformin, glyburide, irbesartan, and amitriptyline. After admission, the patient continued taking CR oxycodone, and several other pain medications (including fentanyl patch) were initiated, as shown in Figure 2.

On the evening of Day 14, the fentanyl dose was increased. Overnight, the patient did not sleep well and was awake for part of the night. On the morning of Day 15, she was left to sleep and was not awakened for breakfast or for usual medication administration. She was found with vital signs absent at about 11 am. Resuscitative efforts were unsuccessful.

The cause of death was determined to be "mixed drug toxicity" on the basis of autopsy and toxicology findings. This determination of mixed drug toxicity takes into consideration the toxicological findings and the combined effects of several of the medications detected post mortem.

ISMP CANADA'S FINDINGS


An interdisciplinary review identified several system-based vulnerabilities and factors potentially contributing to the patient's death. Key opportunities to prevent future deaths were thought to be related to the overall approach to pain management, including opioid selection, dose conversion and titration, and monitoring of symptoms and adverse effects. These opportunities, along with other selected factors, are highlighted in the current bulletin.

APPROACH TO PAIN MANAGEMENT

Opioid Selection


The hospital did not have a standardized protocol for pain management, and the patient's pain was being managed with several different opioid analgesics and a

Figure 1. Timeline of known opioid use in the week leading up to hospital admission (according to available prescription records).



CR = controlled-release

Figure 2. Timeline of use of opioids and other regularly scheduled adjunct medications during the hospital admission



*the daily dose of CR oxycodone varied from 40 to 80 mg until it was discontinued on Day 12 IV = intravenously; SC = subcutaneously

number of adjunctive agents (amitriptyline, cyclobenzaprine, gabapentin, and naproxen). Use of more than one opioid at the same time increases the complexity of dosing and titration and complicates conversion from one opioid to another.

Of particular concern was the use of a fentanyl patch for a patient whose analgesic needs had not been fully determined. Other concerns included the initial and titration doses of fentanyl, concomitant use of more than one long-acting opioid, absence of orders to address breakthrough or variable pain, and use of adjunctive agents with sedative properties without a corresponding reduction in opioid dosage.

Opioid Dose Conversion and Titration

Initial and titration doses (based on generally accepted conversion factors) used in this case were higher than doses recommended in available protocols.^{1,2} Calculation of "morphine equivalents" provides a way to compare the relative potency of other opioids with that of morphine. This calculation is particularly important for converting from one opioid to another and for evaluating the total opioid dose when multiple opioids are being used concurrently. Research has shown that doses of opioids exceeding the equivalent of 200 mg of oral morphine daily are associated with an increased risk of opioid-related death.³ This research has also

shown that calculation of morphine equivalents can help the practitioner to assess whether a patient's overall opioid dose is reaching levels that might cause concern.

On the basis of available prescription records and information provided by the patient at the time of admission, the reviewers estimated that the 24-hour oral morphine equivalent on the day before admission was 120 mg. By Day 3 and for the remainder of the admission, the daily morphine equivalent was calculated to be well over 300 mg, and rose to over 400 mg with the increase in the fentanyl dose on

Day 14. On the day of death (Day 15), it was estimated that the patient would have received the equivalent of 540 mg/day of morphine, if the full dose of fentanyl had been given as prescribed. However, this is a conservative estimate, as one manufacturer's conversion guideline indicates that a 75 mcg/h fentanyl patch is equivalent to a range of 270 to 314 mg oral morphine.²

Despite the high doses of opioids received during her hospital stay, the patient continued to complain of pain. There is a common misperception among health care professionals that patients who continue to experience pain, despite receiving pain medications, are not at risk of opioid toxicity. For such patients, opioids can indeed be titrated to very high doses, but the titration must be done slowly and carefully to avoid toxic effects. The total opioid dose (in terms of estimated morphine equivalents) placed this patient at high risk of opioid-related toxicity and death.

Changing from one opioid to another and selecting an appropriate dose of the next opioid is an inexact science and the selection of a particular conversion factor can have a profound effect on the suggested dose of the intended opioid. For example, hydromorphone is considered to be 4 to 8 times more potent than morphine, so 10 mg of hydromorphone is equivalent to a morphine dose of 40 mg to 80 mg.^{4,5} Depending upon the conversion factor used in a particular guideline, this difference can also have a profound effect on the dosing of other opioids, such as fentanyl patches. Incomplete cross-tolerance, whereby a patient may be more sensitive to the same relative potency of the new opioid than the previous agent, must also be taken into account. A number of guidelines and web-based applications are available to support calculation of conversions from one opioid to another; however, a wide range of conversion factors are used in these guidelines and programs. Having another practitioner, such as a pharmacist, independently perform the conversion calculations can be a valuable safeguard.

Monitoring of Symptoms and Adverse Effects

Formal and consistent evidence of pain and symptom assessment, systematic determination of the effectiveness of analgesics, and routine evaluation for opioid toxicity were not apparent in the nursing or medical notes available for this patient. Vital signs were documented at most once daily, and no vital signs were documented on 5 separate days during the patient's hospital stay. On those days when vital signs were obtained, the documented heart rate was above the upper limit of the normal range. Patient monitoring and assessment were compromised by approved leaves of absence during the admission, whereby the patient was absent from the hospital for most of the day on nearly every day of the admission.

During her hospitalization, the patient expressed concern about how her medication therapy made her feel to the care team and to her family and friends. She reported feeling "wobbly", "unsteady", "groggy", and "whacked out". Despite these voiced concerns, staff members noted that the patient appeared to function fairly well, both physically and cognitively. The medical record included few notes related to the symptoms of toxicity. Where symptoms potentially attributable to medication toxicity were documented (e.g., one instance of noticeable unsteadiness and another instance of the patient being found slumped over in her chair), there did not appear to have been any follow-up with the attending physician. An impending opioid overdose may be difficult to detect because patients may appear to be alert when engaged, despite exhibiting signs of toxicity. These patients are at risk for succumbing to the overdose when left unmonitored.

OTHER FACTORS

Resuscitation Process

The health record indicated that when the patient was found without vital signs, it was presumed, because of her medical history and risk factors that a cardiac event had occurred. The opioid reversal agent naloxone was not administered during resuscitation efforts.

Organizational Factors

The death occurred in a small hospital in a remote community. Access to advanced diagnostic modalities and specialist care is often limited in such communities,

and these factors are difficult to mitigate. In this case, access to a neurologist or pain specialist via remote consultation could have been beneficial.

At the time of this incident, there was no process in place for routine review by a pharmacist of inpatient medication orders at this hospital, a gap that has now been addressed. The importance of independent review of medication orders was highlighted in early patient safety work, which showed that nearly 40% of medication errors occur at the prescribing stage, and of these, nearly half are intercepted through review by nurses and pharmacists. In the community where this patient lived, a pharmacist was not available, which meant that physicians both prescribed and dispensed medications without independent review by a second practitioner.

In addition, the patient was a healthcare provider in the community, which may have influenced decision making on issuing leaves of absence from the hospital.

RECOMMENDATIONS

A number of recommendations were offered for consideration in this case. Those recommendations thought to be generally applicable to all acute care hospitals are presented here.

Pain Management

- Develop or adopt predefined order sets and protocols for pain management. Ensure that order sets include guidance on opioid selection, recommended initial doses (with consideration of patient risk factors), guidance for dose titration, specific monitoring requirements, and triggers for intervention. Protocols should specifically state that the transdermal fentanyl patch should not be used for management of acute or acute-on-chronic pain.
- Ensure that all medication orders are reviewed by a pharmacist in a timely manner, with particular attention to orders for high-alert medications such as opioids. The review of opioid orders should include a review of opioid tolerance and morphine equivalents.
- Consider consulting an experienced opioid prescriber (e.g., acute pain service) if the patient's daily opioid needs are greater than the equivalent of 80 to 120 mg of oral morphine, especially in cases where the patient's pain and function have not improved.⁷
- Undertake a detailed assessment of all processes associated with the management of opioids, including prescribing, order processing, dispensing, administration, and monitoring. Use the results of the assess-

- ment to identify and address vulnerabilities in opioid management.
- Develop clear policies and processes for management of pain medications required during a patient's leave of absence in the course of an admission. Existing policies related to the criteria for granting leaves of absence should be reviewed to ensure appropriate consideration to the need for patient monitoring and establishment of a standard period for a leave of absence, when granted.
- Provide ongoing education for all staff about the signs and symptoms of opioid overdose.
- Consideration should always be given to nonpharmacologic treatment options to manage pain.

Patient Monitoring

- Establish clear expectations for assessment of vital signs and their documentation in the health record for patients who are receiving opioids. When developing protocols for assessment and monitoring, consider the requirements for the initial period of opioid therapy, the period after a dose increase, and when concomitant medications that may depress respiration are added.
- Establish clear processes for assessment and documentation of pain level and the patient's response to any analgesics administered. Assessment and documentation processes should establish expectations for all members of the care team.
- Provide patients and family members with information about the signs and symptoms of opioid toxicity and when to seek medical attention. An example of a patient handout developed by ISMP Canada can be found at http://www.ismp-canada.org/download/HYDRO morphone/ISMPCanada_ OpioidInformationFor PatientsAndFamilies.pdf, and a video is available from: http://youtu.be/SDMz4lqnpPk.

Resuscitation

- Develop medical directives and protocols for the use of naloxone to ensure appropriate and timely management of opioid overdose when a need for intervention is identified.
- Ensure that naloxone administration is considered in resuscitation protocols.

Product Documentation (for Manufacturers)

 Revise monographs and conversion tables for fentanyl patches to indicate that these tables are for initial dose conversion only and emphasize that subsequent titration doses should never exceed 25 mcg/h.

CONCLUSION

The use of opioids to manage pain is a complex process. Previous ISMP Canada Safety Bulletins have highlighted important aspects of numerous harmful incidents associated with opioids, in particular underappreciation of the potency of hydromorphone and fentanyl.^{8,9} It is challenging to balance the desired outcomes of a medication regimen comprising several drug classes with mitigation of the adverse effects and potential interactions that can arise when medications with overlapping toxicities are combined. The concurrent use of more than one opioid further increases the complexity of initial dosing and dose titration. In addition, conversion calculations can be cumbersome and are prone to error. The importance of independent review of dose-conversion calculations, as can be accomplished through timely review of medication orders by a pharmacist, cannot be overstated.

The case presented here illustrates the importance of a clear care plan and a stepwise approach to managing pain that considers initial opioid selection, dose conversion and titration, monitoring parameters, and triggers for intervention, with appropriate interdisciplinary and consultative support. Readers are encouraged to use this bulletin to support review of internal processes associated with opioids in their own practice settings to avoid similar tragic events.

ACKNOWLEDGEMENTS

ISMP Canada gratefully acknowledges the following individuals for their expert review of this bulletin (in alphabetical order):

Matthew Bowes MD, Chief Medical Examiner, Nova Scotia Medical Examiner Service, Halifax, NS; Dan Cass MD FRCPC, former Deputy Chief Coroner − Investigations and Chair, Patient Safety Review Committee, Office of the Chief Coroner for Ontario, Toronto, ON; Meldon Kahan, MD CCFP FRCPC, Medical Director, Substance Use Service Women's College Hospital, Toronto, ON; Paul-André Perron PhD, conseiller en recherche, Bureau du coroner en chef du Québec, Québec, QC; and R. Kent Stewart, Chief Coroner of Saskatchewan, Regina, SK. ■

REFERENCES

- Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Version 5.6. Hamilton (ON): National Opioid Use Guideline Group; 2010 Apr 30 [cited 2014 Jul 15]. Available from: http://nationalpaincentre.mcmaster.ca/ documents/opioid_guideline_part_b_v5_6.pdf
- DURAGESIC MAT (fentanyl transdermal system) [product monograph]. Markham (ON): Janssen Inc; 2014 Aug 5[cited 2014 Sept 15]. Available from: http://www.janssen.ca/ product/114
- 3. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686-691.
- 4. Opioid conversion table. In: Drug information handbook with international trade names index. 23rd edition. Hudson (OH): Lexi-Comp; 2014. p. 2309.
- Opioids [monograph]. In: Repchinsky C, editor-in-chief.
 Compendium of pharmaceuticals and specialties. Ottawa (ON):
 Canadian Pharmacists Association; 2013. p.1950.

- Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995;274(1):35-43.
- Franklin GM. Opioids for chronic noncancer pain: A position paper of the American Academy of Neurology. Neurology. 2014;83;1277-1284.
- Identifying knowledge deficits related to HYDROmorphone. ISMP Can Saf Bull 2012 [cited 2014 Jul 16];12(7):1 Available from: http://www.ismp-canada.org/download/safetyBulletins/2012/ISMPCSB2012 17_IdentifyingKnowledgeDeficits-HYDROmorphone.pdf
- Transdermal fentanyl: a misunderstood dosage form. ISMP Can Saf Bull 2006 [cited 2014 Jul 16];6(5):1-3. Available from: http://www.ismp-canada.org/download/safetyBulletins/ ISMPCSB2006-05Fentanyl.pdf

Respect for Patients on Opioid Agonist Maintenance Treatments (OAMT):

No Place for Stigma

5 THINGS TO KNOW

Anne Kalvik, Pearl Isaac Centre for Addiction and Mental Health Leslie Dan Faculty of Pharmacy



It's important for pharmacists to know that their interaction with patients is a therapeutic moment that can be beneficial or detrimental, depending on their attitude. Some of Toronto's great community pharmacists have a significant impact on recovery and these positive relationships certainly promote patient retention!

Dale Wiebe
Physician, Addiction Medicine Service, CAMH.

Stigma refers to negative attitudes and behaviours towards people including those treated with buprenorphine or methadone for opioid use disorders.¹ Stigma may be based on fear or the belief that somehow "these people brought this (i.e. their addiction) upon themselves". Pharmacists involved in the treatment of opioid dependence need to recognize that "a non-judgmental and non-stigmatizing attitude towards this area of healthcare is an essential starting point for quality care"^{3,4} Pharmacists and other pharmacy staff need to ensure that there is no place for stigma in their practice as they deliver their professional service to this or any group of patients.^{4,5}



Stigma has a negative effect on patient recovery.

Pharmacists' understanding of how stigma negatively impacts patient outcomes, can inform how they interact with patients especially in view of their frequent contact with patients in Opioid Agonist Maintenance Treatments (OAMT).



All pharmacy staff needs to be 'on board' with delivering professional, courteous, sensitive, supportive and non-judgmental care. Conversations, both among staff and with patients, should remain respectful at all times. Patients often overhear how and what is discussed in the dispensary.

Pharmacy staff should also be aware that many maintenance patients, both male and female, come to treatment with a history of trauma. Many have not been treated well by healthcare providers in the past. This may help to explain disruptive behaviours that are sometimes seen in the pharmacy. Some useful strategies may be to remember to be proactive in explaining procedures/expectations in the pharmacy, showing empathy, offering patients' choices and support, and not making assumptions. Focusing on concern for the patient and using motivational interviewing techniques may help to de-escalate difficult circumstances. Modelling appropriate behaviour can help create a climate of mutual respect.



Patients are sensitive to how they are treated by pharmacy staff.

Wait Times: Patients may misinterpret longer wait times as a sign of stigma. Prepare your patients in case they have to wait longer than other patients. There's a lot of work involved in dosing a maintenance patient—checking pattern of dosing, evaluating condition of patients, etc. This may end up taking more time than is spent for other patients in the pharmacy. It is important that pharmacy staff prepare patients for this and indicate that this is not because the pharmacy "serves other patients first". Continuing communication is very important.

Privacy: It's useful for pharmacy staff to discuss ahead of time why it might be preferable that patients on OAMT receive their doses in a private area. Checking under the tongue to see if a buprenorphine dose is dissolved may be problematic if other patients are in the vicinity. Drinking a methadone dose from a cup may lead other patients to ask inappropriate questions. Most patients value privacy while others may be comfortable with discrete respectful dosing in an open area.



Instilling hope and belief in the benefits of opioid dependence treatment can improve outcomes. Recovery takes time. It's unrealistic to expect perfect adherence to the treatment regimen. Remember most patients with chronic illnesses such as hypertension or diabetes have challenges in this regard as well. Language is important. Patients who have suboptimal adherence with other medical conditions are not stigmatized for this to the same extent as OAMT patients may be. For instance, someone with diabetes may have an "elevated glucose level", but someone with an opioid use disorder may be described as having a "dirty urine" sample.²



Relapse happens. Substance use disorder is, by its nature, defined as a chronic and relapsing disorder. Relapse is to be expected and should be regarded as an opportunity to learn how to manage differently in the future, not as "failure". Patients should not be stigmatized if they have a lapse or a relapse. Retention in treatment is one important measure of success in this field. Pharmacy staff can help their patients by supporting them to make positive changes going forward. Patients have a tough time managing relapse and healthcare providers should not be discouraged when this happens. Pharmacy staff plays an important role in encouraging positive change.

REFERENCES

- 1.Stigma (Centre for Addiction and Mental Health)
 http://www.camh.ca/en/education/about/camh_publications/Documents/Flat_PDFs/Stigma_brochure.pdf
- Kelly, JF, Wakeman SE, Saitzman, R "Clinicians, Language, and Quality of Care for the Leading Cause of Preventable Death in the United States" Am J Med, Jan. 2015, 128; (1), p 8-9.
- 3. Sheridan, J. & Strang, J. Eds. (2003). Drug Misuse and Community Pharmacy. London, UK: Taylor & Francis.
- Methadone Maintenance Treatment: Recommendations for Enhancing Pharmacy Services, CAMH, 2009 http://knowledgex.camh.net/ policy_health/substance_use/mmt_enhancing_pharmacy_services/Pages/default.aspx
- 5. Van Boekel et al, Stigma amongst Health Professionals towards patients with Substance use Disorders and its Consequences for health care delivery: A systematic Review, Drug and Alc Dep 2013, 131;(1-2);p 23-36; http://refhub.elsevier.com/ S0002-9343(14)00770-0/sref4

DISCIPLINE DECISIONS



Member: Amany Hanna, R.Ph.

At a hearing held on November 3, 2014 and November 4, 2014, a Panel of the Discipline Committee made findings of professional misconduct against Ms. Hanna in that she

- was found guilty on March 21, 2012 to a charge of fraud over \$5,000, contrary to the Criminal Code, s. 380(1)(a):
- submitted false claims to the Ontario Drug Benefit Program totaling approximately \$200,000 for 20 different drug products that were not actually dispensed to patients, in or about January 2008-October 2009;
- created false records of dispensing and/or billing transactions in relation to the false claims submitted to the Ontario Drug Benefit program, in or about January 2008-October 2009; and/or
- provided false information and documentation regarding drug purchases from Main Drug Mart,
 Capital Rx and/or Guardian Pharmacy to the Ministry of Health and Long-Term Care in the course of the Ministry's investigation, in or about November 2009-January 2010

In particular, the Panel found that Ms. Hanna:

- was found guilty of an offence that is relevant to her suitability to practise;
- failed to maintain a standard of practice of the profession;
- falsified a record relating to her practice;
- signed or issued, in her professional capacity, a document that she knew contained a false or misleading statement:
- submitted an account or charge for services that she knew was false or misleading;
- contravened, while engaged in the practice of pharmacy, a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular, the Ontario Drug Benefit Act, ss. 5, 6 and/or 15(1);
- engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all

the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

The Panel imposed an Order which included the following:

1. A reprimand;

- 2. That the Registrar impose specified terms, conditions or limitations on the Member's Certificate of Registration, and in particular:
 - a) that the Member complete successfully, at her own expense, within 12 months of the date of the Order, the ProBE program on Professional/ Problem Based Ethics for healthcare professionals:
 - b) that the Member be prohibited, for a period of 5 years from the date of the Order:
 - i) from acting as a Designated Manager for any pharmacy; and
 - ii) from having any proprietary interest in a pharmacy as a sole proprietor or partner, or director or shareholder in a corporation that owns a pharmacy, or in any other capacity, or receiving any remuneration for her work as a pharmacist, or related in any way to the operation of a pharmacy, other than remuneration based on hourly or weekly rates or salary and in particular, not on the basis of any incentive or bonus for prescription sales.
 - c) that the Member must, for a period of 5 years from the date of the Order, provide a copy of the Discipline Committee's decision to prospective employers where she works more than 10 days out of a 14 day period.
- 3. A suspension of eighteen months, commencing the date of the Order i.e. November 4, 2014;
- 4. Costs to the College in the amount of \$20,000.

In its reprimand to the Member, the Panel noted that it viewed the Member's conduct as an abuse of trust placed in the Member, as a pharmacist. The Panel acknowledged the Member's family circumstances

but stated that those circumstances did not justify the course of action she chose, namely to manipulate the system over an extended period of time to maximize her financial gain. The Panel pointed to the fact the public had paid a price for the Member's avarice, leading to a detrimental impact on the welfare and potential safety of the public. The Panel viewed the Member's conduct as disgraceful, dishonorable and unprofessional. While acknowledging that the suspension the Member had received was significant, the Panel expressed its view that it appropriately addressed the conduct for a first time offender who has the potential for rehabilitation.

Member: Ramez Tawfik, R.Ph.

At a hearing held on December 9 and 10, 2014, a Panel of the Discipline Committee made findings of professional misconduct against Mr. Tawfik in that he

- submitted accounts or charges for services that he knew or ought reasonably to have known were false or misleading to the Ontario Drug Benefit program for one or more drugs and/or products;
- \falsified pharmacy records relating to his practice in relation to claims made to the Ontario Drug Benefit program for one or more drugs and/or products. In particular, the Panel found that Mr. Tawfik:
- failed to maintain a standard of practice of the profession;
- falsified records relating to his practice;
- submitted accounts or charges for services that he knew or reasonably ought to have known to be false or misleading;
- contravened a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular sections 5 and 15(b) of the Ontario Drug Benefits Act, R.S.O. 1990, c. O.10, as amended, and/ or Ontario Regulation 201/96 made thereunder;
- engaged in conduct or performed an act or acts relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

The Panel imposed an Order which included the following:

- 1. A reprimand;
- 2. Directing the Registrar to impose specified terms, conditions or limitations on the Member's Certifi-

- cate of Registration, and in particular,
- (a) that the Member complete successfully within 12 months of the date of the Order, the ProBE Program on Professional/Problem Based Ethics for Healthcare Professionals;
- (b) that the Member shall be prohibited, for a period of 3 years from the date the Order is imposed, from acting as a Designated Manager in any pharmacy;
- (c) the Member shall be required, for a period of 3 years from the date the Order is imposed, to notify the College in writing of any employment in a pharmacy;
- (d) the Member, for a period of 3 years from the date the Order is imposed, shall ensure that his employer has confirmed in writing to the College that they have received and reviewed a copy of the Discipline Committee Panel's decision in this matter and their Order, and confirming the nature of the Member's remuneration.
- 3. A suspension of eight months with one month of the suspension remitted on condition that the Member complete the remedial training cited above. The suspension commences the date of the Order i.e. December 10, 2014;
- 4. Costs to the College in the amount of \$10,000.

In its reprimand, the Panel reminded the Member that integrity and trust are paramount to the profession and, as such, felt it necessary to impress upon the Member the seriousness of his misconduct. The Panel expressed its disappointment with the Member's failure to maintain a standard of practice of the profession with respect to falsifying records, submitting claims for payment to the Ontario Drug Benefit program where no payment was required and committing acts of professional misconduct. The Panel further expressed to the Member that the practice of pharmacy is a privilege that carries with it significant obligations to the public, the profession and to oneself, and that the Member's actions had eroded the public trust in the pharmacy profession.

Member: Leisa Barrett, R.Ph.

At a hearing held on January 12, 2015, a Panel of the Discipline Committee made findings of professional misconduct against Ms. Barrett in that:

• in or about the period from June 30, 2010, to June 27, 2013, she failed to maintain the

- professional boundaries of the pharmacistpatient relationship when she developed a non-professional, personal relationship with a patient, J.S.;
- in or about the period from January 1, 2010, to March 31, 2014, she failed to keep records as required by the Medication Procurement and Inventory Management Policy with respect to the inventory of narcotics and controlled drugs;
- in or about the period from January 1, 2010, to March 31, 2014, she allowed an individual, J.S., whom she knew to be addicted to narcotics and whom she suspected of stealin narcotics from the pharmacy, to have a key to the pharmacy and access to the dispensary area and/or drug vault;

In particular, the Panel found that Ms. Barrett

- failed to maintain a standard of practice of the profession;
- failed to keep records as required respecting her patients:
- contravened, while engaged in the practice of pharmacy, any federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular, section 43 of the Narcotics Control Regulations, C.R.C., c. 104;
- engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

The Panel imposed an Order which included as follows:

- 1. A reprimand;
- 2. Directing the Registrar to impose specified terms, conditions or limitations on the Member's Certificate of Registration, and in particular, that the Member complete successfully with an unconditional pass, at her own expense and within 12 months of the date of the Order, the ProBE Program on Professional/Problem Based Ethics for Healthcare Professionals;
- 3. A suspension of 5 months with 2 months of the suspension remitted on condition that the Member complete the remedial training cited above. The suspension commenced on the date of the Order i.e. January 12, 2015;
- 4. Costs to the College in the amount of \$5,000.00.

In its reprimand to the Member, the Panel reminded the Member that integrity, trust and professional conduct are at the core of the practice of Pharmacy and the delivery of care to the public. Furthermore, the Panel highlighted that pharmacy, as a self-regulated profession, bears the responsibility to ensure the trust of the members of the profession and the public. The Panel stated that it was of the view that the Order imposed on the Member was fair and reasonable, and that the Member's actions were dishonourable, disgraceful and unprofessional.

Member: Lawrence Zachidniak, R.Ph.

At a hearing held on January 13, 2015, a Panel of the Discipline Committee made findings of professional misconduct against Mr. Zachidniak with respect to the following incidents:

- discrepancies in the inventory of narcotics and other controlled drugs, as recorded in the inventory counts conducted between September 2012 and May 2013, and in particular:
 - (i) failing to maintain security of narcotics and other controlled drugs;
 - (ii) failing to maintain accurate records of purchases, sales and remaining inventory for narcotics and other controlled drugs; and/or
 - (iii) failing to make timely reports of losses of narcotics and other controlled drugs to Health Canada; and/or
- discrepancies in methadone administration practices, and in particular:
 - (i) failing to record properly new prescriptions for dosage changes for methadone, including Rx 9398600/Rx 9400957 for the patient, D.C., and/or Rx 9399672/Rx 9400965 for the patient T.Q., on or about May 14-15 2013; and/or
 - (ii) failing to ensure a pharmacist witnessed doses of methadone taken at the pharmacy in or about March-May 2013.

In particular, the Panel found that Mr. Zachidniak

- failed to maintain a standard of practice of the profession;
- failed to keep records as required respecting his patients;
- contravened the Pharmacy Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991 or the regulations under

- those Acts, and in particular, the Drug and Pharmacies Regulation Act, R.S.O. 1990, c.H.4, s. 156;
- contravened a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, including the Narcotic Control Regulations, sections 30, 40, 42 and/or 43, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19, and/or the Food and Drug Regulations, sections G.03.001, G.03.004, G.03.007, G.03.010, G.03.012, G.03.013 and/or G.03.015, under the Food and Drugs Act, R.S.C. 1985 c.F-27, as well as the Narcotic Safety and Awareness Act, 2010, S.O. 2010, Chapter 22, section 11;
- engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

The Panel imposed an Order which included as follows:

- 1. A reprimand;
- 2. Directing the Registrar to impose specified terms, conditions or limitations on the Member's Certificate of Registration, and in particular, that the Member complete successfully the following courses, programs, and instruction, including any evaluations, at his own expense and within 12 months of the date of the Order:
 - a. the CAMH Opioid Dependence Treatment Core Course:
 - Module 5: Practice and Pharmacy Management II (including JP #7-Controlled Drugs and Substances Act) from the Canadian Pharmacy Skills Program II;
 - c. instruction by an experienced pharmacist acceptable to the College regarding comprehensive reconciliation reports for narcotics and other controlled drugs, following review by the Member of written materials to be identified by the College; and,
 - d. session with Gail Siskind, expert in ethical issues for regulated health care professionals, or other expert acceptable to the College, regarding the risk to the public posed by controlled substances, including narcotics and targeted substances, that are missing or cannot otherwise be accounted for in a pharmacy, before which session the Member will review published materials to be identified by the College, and provide copies of the Reasons for Decision and the publications to the expert at least one week in advance of the session.

- 3. Directing the Registrar to impose additional specified terms, conditions or limitations on the Member's Certificate of Registration requiring the Member to demonstrate following the instruction in paragraph 2 (c) that he has understood and put into practice the requirements for comprehensive reconciliation reports by providing at least four examples of such reports acceptable to the College that have been prepared by him during the 12-month period following the date of the instruction
- 4. Directing the Registrar to impose additional specified terms, conditions or limitations on the Member's Certificate of Registration restricting the Member from having ownership interest in any pharmacy, or being the Designated Manager of any pharmacy, for a period of three years from the date of this Order, with one year of the restrictions to be remitted on condition that the Member complete the courses, programs and instruction set out in paragraphs 2 and 3 above as specified.
- 5. A suspension of 3 months with 1 month of the suspension to be remitted on condition that the Member complete the remedial training cited in paragraph 2 above. The suspension commences on January 14, 2015;
- 6. Costs to the College in the amount of \$3,000.00.

In its reprimand, the Panel reminded the Member that integrity and trust is paramount in the profession of pharmacy. The Panel stated its disappointment in the Member, noting that the Panel was quite shocked by the lack of control over narcotics for which the Member was responsible, suggesting that the Member had acted in a cavalier manner. The Panel stated its expectation that the Member would complete the remedial actions in the agreed upon time frame and use the opportunity to improve his professional conduct.

The full text of these decisions is available at www.canlii.org

CanLii is a non-profit organization managed by the Federation of Law Societies of Canada. CanLii's goal is to make Canadian law accessible for free on the Internet.

FOCUS ON ERROR PREVENTION

By Ian Stewart B.Sc.Phm., R.Ph.

SIMILAR DRUG NAMES

The similarity of drug names is a common factor in the dispensing of an incorrect drug. Poor verbal or written skills can increase the risk of errors involving drugs with similar names.

CASE:

A sixty year-old patient has been taking Valsartan 40mg once daily for an extended period of time. On a recent visit to his family physician, he was given a prescription for Telmisartan 40mg once daily. The prescription was taken to his regular pharmacy for processing.

As per the prescription, 90 Telmisartan 40mg was prepared and dispensed to the patient. The patient was asked if he would like to speak to the pharmacist. He replied that he did not because he has been taking the medication for some time.

The patient therefore took the Telmisartan home in the bag provided. Two days later, the patient opened the bag to take the medication and notice that the tablets were different to the Valsartan that he had been taking. He therefore contacted the pharmacy to inquire regarding the change in medication. After confirming that the pharmacy did dispense the drug

that was prescribed, a call was made to the prescriber. The doctor confirmed that he did not intend to change the patient's drug therapy, and wanted Valsartan 40mg to be dispensed as previous.

POSSIBLE CONTRIBUTING FACTORS:

- Valsartan and Telmisartan have similar names, indications and strengths (40mg).
- The patient's medication history was not consulted by the pharmacy assistant entering the prescription or the pharmacist checking the prescription to identify any changes in drug therapy.
- The patient did not receive counselling though the pharmacy believed that he did not take the medication previously.

RECOMMENDATIONS:

- Be aware of the potential for error when dispensing drugs with similar names. To the left is an abbreviated list of problematic drug pairs. A more comprehensive list can be accessed at: http://www.ismp.org/tools/confuseddrugnames.pdf. Accessed Jan. 30, 2015.
- The patient's medication history should be consulted to identify changes in drug therapy or potential prescribing errors.
- New drug therapy should be flagged to ensure the
 patient receives the appropriate counselling. If the
 patient indicates they have the taking the medication,
 investigate the discrepancy.
- Advise pharmacy staff to avoid asking patients receiving new drug therapy if they would like to speak with the pharmacist. Patients in a hurry may simply say no. Hence, an opportunity to provide much needed information and to catch a potential error is missed. Instead, the patient can be informed that "the pharmacist would like to speak with you regarding your medication."

Please continue to send reports of medication errors in confidence to lan Stewart at: ian.stewart2@rogers.com. Please ensure that all identifying information (e.g. patient name, pharmacy name, healthcare provider name, etc.) are removed before submitting.

STRUCTURED PRACTICAL TRAINING:

Now and the Future

As one of the registration requirements to become a pharmacist or pharmacy technician in Ontario, Structured Practical Training (SPT) allows registered pharmacy students, interns and pharmacy technician applicants (preceptees) to develop and demonstrate their competence for entry-to-practice and prepares them for the transition into independent practice. It is a requirement that they all have to complete, regardless of where they completed their education. This requirement can be met either by completing the College's SPT Program or through other experiential rotations that have been approved by Council. Examples of this include the entry-level PharmD programs at the universities of Toronto and Waterloo, whose programs continue to evolve and allow significant opportunities for students to engage in practice through experiential training rotations at an advanced level

Within OCP's SPT Program, preceptees complete various activities over the course of 12 weeks that are based in practice so that they have an opportunity to engage in the full scope of the profession under the supervision of a trained preceptor. Throughout the training, the preceptors will guide, help develop and most importantly, assess the performance of their preceptee to determine if they have demonstrated the competencies necessary to practice as an independent pharmacist or pharmacy technician.

Moving forward, the College has been looking to make significant changes to the SPT Program as a result of the formal evaluation that was conducted on the program. This was done to allow the College to ensure that its requirements are fair and necessary while also ensuring public protection. It was found that the SPT Program is effective in providing opportunities to develop and demonstrate competence and prepare for independent practice. However, the review also found that SPT should not be based around a one-size fits all model, which requires everyone to undergo training. From those findings, the College has been working to redesign the program to become a truly competency-based model.

This means that the College is looking to offer a program that begins with an assessment to determine competence for practice. Training would only be required if gaps are identified which require development. Either the individual will have met the SPT requirement by the end of the assessment or they will enter into a period of self-directed training before being reassessed.

The College is in the process of piloting the new program this spring and will be evaluating it to ensure that it meets the desired outcomes. For more information, or to participate in the pilot, please send an email to regprograms@ocpinfo.com.

Thank You Preceptors

Pharmacists and pharmacy technicians consistently demonstrate commitment to their students, interns and pharmacy technician applicants – and to the profession – by fulfilling their roles as preceptors in the SPT Program. 2014 was no exception. The tremendous dedication our preceptors put forward in supporting future colleagues is the backbone of the program and is pivotal to its success. Thank you, preceptors.

To add your name to future lists of appreciations, please contact the Registration Programs department.

AJAX	Engels, Dinie	Quinta Health Care
Cassin, Tammy	Fearman, Jessica	
Chen, Bowen	Galloway, Vaughn	
Cook, Laurie	Gao, Sherrie	
Garcha, PatrickShoppers Drug Mart	Guimbatan, Lloyd	
Ghassemi, AmirCostco Pharmacy	Heravi, Samira	
Hanna, GeorgeMedical Place Pharmacy	Kelly, Ashley	
Jaffry, HaiderCostco Pharmacy	Parker, Nicole	
Juma, Shafina Shoppers Drug Mart	Vieira, Leanne	Quinte Health Care
Mavadia, Asmita		
McQuaid, Patricia	BOBCAYGEON	
Torchia, Rosamaria Ajax Pickering Health Centre	Tan. Phong	Village Gate Pharmasave
, ,	, , , , , , , , , , , , , , , , , , ,	
ALLISTON	BOLTON	
Shah, Ketan	Awad Medhat	Total Health Pharmacy
Wong, Johnny	Desai, Virenkumar	
	,	,
AMHERSTBURG	BOWMANVILLE	
Wolff, MaryShoppers Drug Mart	Paul Wendy	Bowmanville Clinic Pharmacy Limited
,,	Zhao, Nan	
AMHERSTVIEW	Bracebridge	,
Patel, Jagrutiben Shoppers Drug Mart		South Muskoka Memorial Hospital
Patel, Jagi otiberi	coker, reny	
ANCASTER	BRADFORD	
Agwa, Lydia	Arrigo, Anne	Rexall
Gilbertson, Amanda	Gill, Stephen	
Kakkar, Varun	Kent, Jacqueline	Rexall
MacKinnon, Jesse Costco Pharmacy	· ·	
· · · · · · · · · · · · · · · · · · ·	BRAMPTON	
ANGUS	Ahmed, Seema	Costco Pharmacy
Privado, CristinaRainbow Pharmasave		Brampton Civic Hospital
Thread, cristina		Father Tobin Pharmacy
ARNPRIOR		Brampton Civic Hospital
Dombroski, Courtney Rexall		Healthplex Pharmacy
Donibi Oski, Cool tiley	Bhatti, Balpreet	Shoppers Drug Mart
ASTRA	Briganti, Cinzia	Brampton Civic Hospital
Clark, Frederick24 Canadian Forces Health Services Centre	Buendia, Conni	Kings Cross Pharmacy
Clark, Frederick24 Canadian Forces Health Services Centre	Ceci, Ada	Rexall
AURORA	Chowdhury, Farzana	Drugstore Pharmacy
	Darji, Dharmegn	
Azemodeh Ardlan, Elaheh		Pharmasave Bramcity Pharmacy
Chaudary, Faraz	D'Souza, Sandra	
Lui, Kai		Brampton Civic Hospital
Onizuka, David	Hanna, Rania	
Pang, Vincent	Hernane, James	
Piquette, CindyShoppers Drug Mart	Karmali, Sadiq	
Shenouda, JohnHollandview Pharmacy	Kaushik, Ram	
Sheriooda, 30mi Holiandwiew i Harmacy	Kazmı, Jawaırıa	The state of the s
AZILDA	Khachh, Sharanjit	
	_	Queen-Lynch Pharmacy
Chiu, Jacqueline	Kondoor, Sunitha	
BANCROFT	Mahmood, Saima	
	·	Castlemore Pharmacy
Bansal, VineyShoppers Drug Mart	Manroy, Gagandeep	,
DADDIE		Shoppers Drug Mart
BARRIE	Midha, Amarjit	Shoppers Drug Mart
Al-Akeedi, FarisCostco Pharmacy	Midha, Amarjit Mikhael, Marian	Shoppers Drug Mart Brampton Civic Hospital
Al-Akeedi, Faris	Midha, Amarjit	Shoppers Drug Mart Brampton Civic Hospital Shoppers Drug Mart
Al-Akeedi, Faris	Midha, Amarjit. Mikhael, Marian Nejat, Jinous. Nolan, Kelly	Shoppers Drug MartBrampton Civic HospitalShoppers Drug MartAvita Integrative Health & Restoration Clinic
Al-Akeedi, Faris	Midha, Amarjit	Shoppers Drug MartBrampton Civic HospitalShoppers Drug MartAvita Integrative Health & Restoration ClinicSpringdale Pharmacy
Al-Akeedi, Faris	Midha, Amarjit	Shoppers Drug MartBrampton Civic HospitalShoppers Drug MartAvita Integrative Health & Restoration ClinicSpringdale PharmacyBrameast Pharmacy
Al-Akeedi, Faris	Midha, Amarjit. Mikhael, Marian Nejat, Jinous. Nolan, Kelly Oliveiro, Christopher Patel, Nisha Patel, Sangeeta.	Shoppers Drug MartBrampton Civic HospitalShoppers Drug MartAvita Integrative Health & Restoration ClinicSpringdale PharmacyBrameast PharmacyClinik Pharmacy
Al-Akeedi, Faris	Midha, Amarjit. Mikhael, Marian Nejat, Jinous. Nolan, Kelly Oliveiro, Christopher Patel, Nisha Patel, Sangeeta. Riar, Nina	Shoppers Drug MartBrampton Civic HospitalShoppers Drug MartAvita Integrative Health & Restoration ClinicSpringdale PharmacyBrameast PharmacyClinik PharmacyTarget Pharmacy
Al-Akeedi, Faris	Midha, Amarjit. Mikhael, Marian Nejat, Jinous. Nolan, Kelly Oliveiro, Christopher Patel, Nisha Patel, Sangeeta. Riar, Nina Rizarri, Ethel	Shoppers Drug MartBrampton Civic HospitalShoppers Drug MartAvita Integrative Health & Restoration ClinicSpringdale PharmacyBrameast PharmacyClinik PharmacyTarget PharmacyShoppers Drug Mart
Al-Akeedi, Faris	Midha, Amarjit	Shoppers Drug MartBrampton Civic HospitalShoppers Drug MartAvita Integrative Health & Restoration ClinicSpringdale PharmacyBrameast PharmacyClinik PharmacyTarget PharmacyShoppers Drug MartBrampton Civic Hospital
Al-Akeedi, Faris	Midha, Amarjit	
Al-Akeedi, Faris	Midha, Amarjit	
Al-Akeedi, Faris	Midha, Amarjit	Shoppers Drug Mart Brampton Civic Hospital Shoppers Drug Mart Avita Integrative Health & Restoration Clinic Springdale Pharmacy Brameast Pharmacy Clinik Pharmacy Target Pharmacy Shoppers Drug Mart Brampton Civic Hospital Brampton Civic Hospital Shoppers Drug Mart Shoppers Drug Mart Wal-Mart Pharmacy
Al-Akeedi, Faris	Midha, Amarjit	Shoppers Drug Mart Brampton Civic Hospital Shoppers Drug Mart Avita Integrative Health & Restoration Clinic Springdale Pharmacy Brameast Pharmacy Clinik Pharmacy Target Pharmacy Shoppers Drug Mart Brampton Civic Hospital Brampton Civic Hospital Shoppers Drug Mart Wal-Mart Pharmacy Wal-Mart Pharmacy
Al-Akeedi, Faris	Midha, Amarjit Mikhael, Marian Nejat, Jinous Nolan, Kelly Oliveiro, Christopher Patel, Nisha Patel, Sangeeta Riar, Nina Rizarri, Ethel Rizvi, Asif. Sachdeva, Jagmohan Salama, Heba Salem, Fatema San Jose, Maila	Shoppers Drug Mart Brampton Civic Hospital Shoppers Drug Mart Avita Integrative Health & Restoration Clinic Springdale Pharmacy Clinik Pharmacy Clinik Pharmacy Target Pharmacy Shoppers Drug Mart Brampton Civic Hospital Brampton Civic Hospital Shoppers Drug Mart Wal-Mart Pharmacy Wal-Mart Pharmacy Shoppers Drug Mart
Al-Akeedi, Faris	Midha, Amarjit. Mikhael, Marian Nejat, Jinous. Nolan, Kelly Oliveiro, Christopher Patel, Nisha Patel, Sangeeta. Riar, Nina Rizarri, Ethel Rizvi, Asif Sachdeva, Jagmohan Salama, Heba Salem, Fatema San Jose, Maila. Sehdev, Naresh Shukla, Piyushkumar.	Shoppers Drug Mart Brampton Civic Hospital Shoppers Drug Mart Avita Integrative Health & Restoration Clinic Springdale Pharmacy Clinik Pharmacy Clinik Pharmacy Target Pharmacy Shoppers Drug Mart Brampton Civic Hospital Brampton Civic Hospital Shoppers Drug Mart Wal-Mart Pharmacy Wal-Mart Pharmacy Shoppers Drug Mart

PRECEPTORS

Singh, Devinder	Shoppers Drug Mart	CHATHAM
Singh, Parvinder	Bramcentre Pharmacy	Chopra, SanjeevLoblaw Pharmacy
Sodhi, Jaspreet	Shoppers Drug Mart	Collodel, Michael
Wang, Sharon	Shoppers Drug Mart	Deroo, Gary
Yousef, Joseph	Sandalwood Medical Pharmacy	Dovancescu, MonicaShoppers Drug Mart
		Johnston, Janet
BRANTFORD		Meades, JenniferMedical Place Pharmacy
Asad. Irene	Brantford Medical Pharmacy	· ·
	The Brantford General Hospital	CHELMSFORD
	Colborne Pharmacy & Medical Centre	Gagne, Michelle Loblaw Pharmacy
D'Souza, Jennifer	The Brantford General Hospital	Tetreault, LouiseChelmsford Pharmacy
Manjunath, Santosh Kum	nar Loblaw Pharmacy	,
Meleka, Nervana	Terrace Hill Pharmacy	COBOURG
Morgan, John	Brantford Life Care Pharmacy	Barrett, LeisaThe Medicine Shoppe
Pearson, Jason	The Brantford General Hospital	Barrette, Ecister
Pickering, Crystal	The Brantford General Hospital	COCHRANE
Qayum, Abdul	Wal-Mart Pharmacy	
Steele, Jacqueline	Medisystem Pharmacy	Gravel, Marc-André
Thomson, Tara	The Brantford General Hospital	Louvelle, FrancisJohn Wallace Drug Store
		COLLINGWOOD
BRIGHT'S GROVE	E	
Galloway, Karen	Bright's Grove Family Pharmacy	Matthews, Mark Shoppers Drug Mart
		CONCORD
BROCKVILLE		
Baker, Christine	Shoppers Drug Mart	Adriano, Brenda
Chiu, Jennifer	Brockville General Hospital	Rudakas, TheresaGlen Shields Pharmacy Rusli, AliceGlen Shields Pharmacy
De Murtas, Donnabelle .	Wal-Mart Pharmacy	Waheed, Asim-bin
Leslie, Mark	Shoppers Drug Mart	Yong, Pei
Sham, Lap-wai	Brockville General Hospital	Tong, Felvvai-Mai t Friai macy
PLIDEODD		CONISTON
BURFORD		Giguere, Bryan Coniston Pharmacy
Poreba, Richard	Pharmasave Burford Pharmacy	
BURLINGTON		CORNWALL
		Hanna, AndrewWal-Mart Pharmacy
	Jasmin Pharmacy	Lemay, JoseeMedical Arts Pharmacy
	Maple Pharmacy	Sanghavi, AnishkumarCornwall Community Hospital
-	Innomar Specialty Pharmacy	Trottier, Paul Jean Coutu Pharmacy
	Smartmeds Pharmacy	
	Joseph Brant HospitalSmartmeds Pharmacy	DEEP RIVER
	Smartmeds Pharmacy	Shah, Nina
	Morelli's Pharmacy	
	Shoppers Drug Mart	DELHI
	Mountainside Pharmacy	Stanczyk, John
	Shoppers Drug Mart	Stanczyk, John
	Costco Pharmacy	DON MILLS
· ·	Joseph Brant Hospital	Salehmohamed, Shelina Shoppers Drug Mart
	Wal-Mart Pharmacy	Yoo, PeterShoppers Drug Mart
	Shoppers Drug Mart	Joo, 1 etc
, ,	Shoppers Drug Mart	DORCHESTER
	Joseph Brant Hospital	
Stojanovic-Kojic, Jelena	· · · · · · · · · · · · · · · · · · ·	Molnar, StephenShoppers Drug Mart
	Costco Pharmacy	DOWNSVIEW
	Joseph Brant Hospital	
	Shoppers Drug Mart	Aslam, SohailShoppers Drug Mart
	Innomar Specialty Pharmacy	Boin, Sonya
		Hu, DarrenHumber River Regional Hospital
CAMBRIDGE		Ismail, FatimaNor-Arm Pharmacy
Digiovanni Matthew	Hespeler Pharmacy	Khetia, JaymeshShoppers Drug Mart
	Shoppers Drug Mart	Silver, Avi
	Shoppers Drug Mart	Yip, Linda Shoppers Drug Mart
		DUNDALK
CAMPBELLFORD		
Jahanzeb, Maleeha	Rexall	Hanna, PeterDundalk Village Pharmacy
	Campbellford Memorial Hospital	DUNDAS
CARLETON PLAC	E	Borg, HazelShoppers Drug Mart
Hasan, Debie	Shoppers Drug Mart	Fisher, CaleShoppers Drug Mart
CARP		
VA/I : D	M C L D M	

White, Ryan......West Carleton Drug Mart

DUNNVILLE		GANANOQUE	
Gurney, Susan	Haldimand War Memorial Hospital Rexall	Tang, Jean	Pharmasave
•		GARSON	
EAST GWILLIMBURY		Jussila, Tammi	Nickel Centre Pharmacy
Ayoub, Diana			
Hanna, Christine	*	GEORGETOWN	
Saifi, Parinaz	Costco Pharmacy		Young's Pharmacy And Homecare
EAST YORK		Trigiani, Anne	Halton Healthcare
	V() D D	CLOUGESTER	
Lum, Walter	Victoria Park Pharmacy	GLOUCESTER	
EGANVILLE		Bhatti, Sarah	
Ritchie, Debra	Conways Pharmasy	Crotty, Kelly Padura, Schenneth	
Roosen, Shannon		Fadora, Scrienneur	Rexaii
rtooseri, Sridinion	comays i narmacy	GODERICH	
ELLIOT LAKE		Asher, John	Rexall Pharma Plus
Angus, Peter	Rexall	75161, 301111	
-	St. Joseph's General Hospital	GRAND BEND	
		Bannerman, James	Grand Bend Pharmacy
ESSEX		· ·	•
Craig, James	Shoppers Drug Mart	GRAVENHURST	
		De Peralta, Clarissa	Shoppers Drug Mart
ETOBICOKE			
Abou Zeid, Ahmed		GUELPH	
	Woodbine Pharmacy Pharmachoice	Abdelmalak, Medhat	
Chan, Christopher			University Square Pharmacy
Der-sahakian, Sylvia		Daniels, Gary	
Eskandar, Wael Alfy Kirllos Fraser, Minglin			Prime Care Pharmacy Arboretum
	Woodbine Pharmacy Pharmachoice	Howard, Theresa	·
	Sherway Medical Pharmacy	Husain, Diary Kidston, Heather	
Mankaruos, Emad		Krusky, Judith	
Mofid, Marjan	•		Prime Care Pharmacy Arboretum
Oseli, Karl	Glen Cade Pharmacy	Manson, Kenneth	
Pamalpadi, Balaji		Nelson, Michele	
	Kipling Heights Pharmacy	Oliver, Jeannine	Kortright Pharmacy
Raheem, Arif		Smith, Jennifer	
Semeniuk, Zita		Yoannus, Nardin	Campus Drugmart
Sourial, Ramy		HALIBURTON	
Sundaramoorthy, Ragavan			5.
Trat, Daniel		Gooley, Lauren	
	Shoppers Simply Pharmacy	Mansfield, Aimee	Shoppers Drug Mart
Wajid, Abdul	Loblaw Pharmacy	HAMILTON	
Wu, Ming		Ahmad, Muhammad Basil	Shappors Drug Mart
Youn, Jie-Young		Anderson-Muwonge, Alecia .	11
Zlydennyy, Vyacheslav	Markland Wood Pharmacy Limited	Birkness, Ravinder	
EXETER		Boneo, Joy	
	Human Apathacaarilad	Chang, Deborah	
Cook, Gerald	nuron Apotnecary Ltd	Cheriyan, Ezzy	
FENELON FALLS		Cheriyan, Renu	11
	Pharmasave Fenelon Falls Pharmacy	Chkaroubo, Anatoli	
ran, Friorig	Haimasave i effetori Falls MidfilldCy	Choi, Hoi.	
FERGUS		Davidson, Susan	Hamilton Health Sciences Corp
Ayoub, Maged	St. Andrew Pharmacy	Deif, Sarah	
	Groves Memorial Community Hospital	D'Silva, Christina	·
	The second secon	Durrani, Saika	,
FONTHILL			St. Joseph's Hospital Outpatient Pharm
Sicoli, Franco	Shoppers Drug Mart	George, Elizabeth	Shoppers Drug Mart
			Hamilton Health Sciences Corp
FORT ERIE		Gunning, Robin	·
De Angelis, Aven	Shoppers Drug Mart	Hanbali, Jafar	
<u> </u>		Ho, Caroline	
FORT FRANCES		Ho, Joseph.	
Cousineau, Stephanie	La Verendrye Health Centre	Hosiassohn, Philip	
Nielson, Kevin		Ishak, Salwa	
		Jankovic, Ivana	•

PRECEPTORS

Kandeil, Marwa	Hamilton General Hospital	KANATA	
Khalil, Hany	Hamilton Community Pharmacy	Gabr, Ghada	Shoppers Drug Mart
Kodsy, Maged	Rexall	MacDonald, Russell	
Kotsios, Damiani		Mardasi, Babak	
Kurian, Betty	•	Taban, Katayoun	
Kurian, Prabha	·	Tran, Jason	
Labelle-Stimac, Sylvie		Wasay, Munaza	-
Labib, Maged	·	Yeo, Sarah	
Le, Kim	•	,	
Lewis, Robert	Hamilton Health Sciences Corp	KEMPTVILLE	
Lo, Allan	Rexall	Yari Pour, Sepideh	Loblaw Pharmacy
Makhova, Daria	Hamilton Health Sciences Corp	lair Fooi, Sepideir	Lobiaw Filaithacy
Marriott, Brittany	Juravinski Hospital	KENORA	
McDiarmid, Tamara	Hamilton Health Sciences Corp		CI D. M.
McGinley, Teresa	Hamilton Health Sciences Corp	English, Ashley	
Nagra, Maninder	Shoppers Drug Mart	Simpkin, Bethany	Snoppers Drug Mart
O'Neal, Leah	Juravinski Hospital	KINCARDINE	
Parihar, Kavita	Hamilton Health Sciences Corp		
Parihar, Vikas	St. Peter's Hospital	Elzinga, Taralee	South Bruce Grey Health Centre
Paterson, Georgina	Hamilton Health Sciences Corp		
Polamreddy, Lalitha	Centre For Mountain Health Sciences	KINGSTON	
Polamreddy, Vijay Sekar	St. Joseph's Hospital Outpatient Pharmacy	Baker, Jennifer	Medical Arts Pharmacy
Roic, Durdica	Rexall	Burke, Elaine	Loblaw Pharmacy
Root, Melissa	Hamilton Health Sciences Corp	Carriere, Julie	Ongwanada Pharmacy
Ross, Ivan	McMaster University Medical Centre	Chong, Sharon	Kingston General Hospital
Safi, Rami	Shoppers Drug Mart	Chong, Yuen Kei	Bioscript Pharmacy Ltd
Sekharan, Santhosh	Rexall	Donnelly, Joel	Medical Arts Pharmacy
Seliskar, Brigit-Ann	McMaster Drugstore	Doyle, Adam	Shoppers Drug Mart
Shamshon, Usama	Lopresti Pharmacy	Giddey, Jana	Kingston General Hospital
Shaw, April	Hamilton Health Sciences Corp	Ho, George	Medisystem Pharmacy
Stevenson, Michelle	Juravinski Hospital	Hussein, Tarek	,
Syed, Khalid	Shoppers Drug Mart	Kerr, Suzanne	-
Tejura, Bhikhu			Kingston General Hospital
Tung, Elizabeth	Hamilton Health Sciences Corp		Kingston General Hospital
Voon, May	Westmount Pharmacy		Medisystem Pharmacy
Wighardt, Zoltan		Luhadia, Priti	
-	Hamilton General Drugstore		Kingston General Hospital
Wood, Alicia		McReelis, Brenden	
Zaki, Ashraf	Queenston Pharmacy	Moretti, Roman	
HANNED			Kingston General Hospital
HANMER		Reynen, Louise	
	Valley Plaza Pharmacy Pharmasave		Kingston General Hospital
Tourigny, Sandra	Loblaw Pharmacy	Schell, Maria	Kingston General Hospital
		Talaat, Gihan	3
HANOVER		Wall, Amanda	,
Patel, Anand	Pharma Plus	VVali, Alfialida	Shoppers Drug Mart
		KITCHENER	
HAWKESBURY		_	St. Mary's General Hospital
Giroux, Francine	Phcie Lise St-Denis Pharmacy		
			The Grand River Hospital
HEARST		Christie, Kyla	•
Brunet, Theresa	Pharmacie Novena	Coutu, Jennifer	Health Care Centre Pharmacy
HUNTSVILLE			The Grand River HospitalThe Grand River Hospital
Cox, Troy	Pharmasave		·
	Muskoka Algonquin Healthcare	Guirguis, Amira	
Murdy, Dana		Hastie, Bryan	
Prordy, Daria	Shoppers Drog Mare	Husain, Diary	
INGERSOLL		Iqbal, Syed Asad	
Parsons, Robert	Dharmagaya		Health Care Centre Pharmacy
		Miller, Christopher	,
Sawler, Christopher	onoppers Drog Mart	·	Centre for Family Medicine
IQALUIT		Patel, Dhananjay	-
	Oilistani Canan III.		The Grand River Hospital
baikie, Laura	Qikiqtani General Hospital	Saad, Maged	·
IDOOLIOIS EALLS A		Saad, Mervat	
IROQUOIS FALLS A		Sampath, Shanthi	-
Bertrand, Brian	Family Care Pharmacy	Thai, John	• • •
JACKSON'S POINT		LAKEFIELD	
Eustace, Peter	Eustace Pharmasave		Lakefield IDA Pharmacy
		1 azzari, Darner	Lakenely IDA Friai IIIdCy

LAKESHORE		Ryerse, Linda	London Health Sciences Centre
Masotti, Lareina	Sobeys Pharmacy	Sashegyi, Hubert	
		Shanghavi, Puja	
LASALLE		Sinclair, Norma	
El-Turk, George		Suleiman, Munir	11 3
Modestino, Roberto	Rexall	Taylor, Grant	
LEAMINISTON		Tompkins, Brian	
LEAMINGTON		Trainor, John	
	Leamington Medical Pharmacy		Regional Mental Health Care - London
Morse, Natalie	*	Van Waes, Shirley	•
Palmer, Jennifer	Leamington District Memorial Hospital	Woo, Stephen	·
LINDSAY		Yadav, Neeta	Shoppers Drug Mart
	D M 1111 5.1	Yausie, Amanda	London Health Sciences Centre
	Ross Memorial Hospital	Zaharia, Angela	Precise Pharmacy
Milbury, Ryan	Ross Memorial Hospital	1116(016)44	
Noorbakhsh, Mahvash		LUCKNOW	
	Remedy's Rx on Kent	O'Krafka, Stephanie	Lucknow Pharmasave
Quan, Chang Ling		MANIOTICI	
3 3	,	MANOTICK	
LISTOWEL		Abdalla, Mohamed	
Niccoli, Pascal	Shoppers Drug Mart	Mortin, Andrea	Paul's Pharmasave
	.,	MAPLE	
LIVELY			M I DI 2 DI
Palys, James	Lively Pharmacy		Medi Pharm 2 Pharmacy
, .	, ,	Dalimonte, Jack	
LONDON			Medi Pharm 2 Pharmacy Medi Pharm 2 Pharmacy
Amadio, Nadia	Shoppers Drug Mart		oonMedi Pharm 2 Pharmacy
Ammoun, Norman	11 3	NOOI wala, Moriaminad Han	oonviedi Friaim 2 Friaimacy
Baskette, John	London Health Sciences Centre	MARKDALE	
Bohdanowicz, Elke	London Health Sciences Centre	Barry, Stephen	Markdalo Dharmacy
Bombassaro, Anne	London Health Sciences Centre	Barry, Stephen	Ividi kudie Pridriliacy
	Pond Mills Medical Pharmacy	MARKHAM	
Chilelli, Ronald	·		Costso Dharmasy
	Greenhills Pharmacy Ltd	Ahmed, Syed Bhana, Hamat	
Coome, Tracy		Cheung, Tina	
*	London Health Sciences Centre	Daoud, Fiby	
Dale, Vasile De Padua, Felvant		,	Bayshore Specialty Rx
	London Health Sciences Centre		Bayshore Specialty Rx
	Oxford Medical Pharmacy	Howe, Christine	Markham Stouffville Hospital
Dhami, Karan		Huynh, Kinh	Shoppers Drug Mart
	London Health Sciences Centre	Jin, Hui	*
Garrick, Cynthia		Khamis, Saleem	
Gurgul, Bogumila	·	Khan, Mohamed	
Jarman, Heather		Leekha, Kamna	
John, Celia	London Health Sciences Centre	Leung, Janet Pui Sea	
	Chapmans Pharmacy	Ma, Jacqueline	
,	London Health Sciences Centre	Patel, Aniket	Markham Stouffville Hospital
Kutz, Daniel		Tafreshi, Newsha	,
	London Health Sciences Centre	Tam, Jonathan	The state of the s
9	Wortley Village Pharmasave		Markham Stouffville Hospital
Lefave, Laura	·	Twfic, Mina	
Li, Beisi	Snoppers Drug MartClassic Care Pharmacy	Vali, Parvaneh	
	London Health Science Centre	Wong, Michelle	-
	London Health Science Centre	Zaidi, Syed Muhammad	
Luo, Vicky			
	Classic Care Pharmacy	MEAFORD	
Maghari, Nabil	· · · · · · · · · · · · · · · · · · ·	Davies, Christopher	Muxlow Pharmacy Limited
-	London Health Sciences Centre		
Muylaert, Mindy	London Health Sciences Centre	MIDLAND	
Nassori, Siamak		Cebrynski, Lara	Loblaw Pharmacy
Neilson, Andrea		Keller, Robert	Clinic Pharmacy
O'Hara, Robert	· ·		Arcade and Jory Guardian Pharmacy
	Medisystem Pharmacy	_	Georgian Bay General Hospital
Prior, Marcie		Tolmie, Michael	Shoppers Drug Mart
	London Health Sciences Centre		
	Masonville Pharmacy		
	London Health Sciences Centre		
Rumble, Philip	Snoppers Drug Mart		

MILTON

Atia, Yehia	Zak's Pharmacy
Hillebrand, Nicolette	Halton Healthcare Services
Johal, Puneet	Halton Healthcare Services
Kular, Manpreet	Medicine Shoppe Pharmacy
Makar, Rania	Milton Square Pharmacy
Philips, Hany	St. George Pharmacy
Shalvardjian, Peter	Shoppers Drug Mart

MICCICCALICA	
MISSISSAUGA	5:
Abd El Malak, Jakleen	
Abdulraheem, Dima	,
Ahmad, Jauher	
Ahmad, Navid	
Ahmad, Sarah	,
Ahmed, Nadeem	•
Awad, Mina	*
Aziz, Ehab	.Marcos Pharmacy
Bath, Jagdeep	.The Credit Valley Hospital
Berbecel, Manuela	
Bining, Narinder	
Cabading, Leonora	
Chambers, Carol	
Cheng, Lucy	
Cheung, Arthur	
Ehteshamnia, Bahar	
El-Hennawy, Reem	
Elsabakhawi, Mohamed	
Esguerra, Monaliza	
Fazeli, Fatemeh	.Loblaw Pharmacy
Ghattas, Mariam	
Gould, Kelly	
Gupta, Chakshu	
	.Credit Valley Family Health Team
Haj-Bakri, Mohamad	•
Hanna, Marian Henein, Maged	
	Guru Nanak Dev Pharmacentre
Hussain, Khurram	
Jaferi, Zehra	
Jankovic, Ksenija	.Shoppers Drug Mart
Kapoor, Shivani	.Express Scripts Canada Pharmacy
Khan, Munawar	
Kim, Jiwon	
Kular, Kulbir	
Lamonica, Vincenzo	
Le, Wayne	
Lee, Ka Man	
Li, Wing	Medical Pharmacy
Li, Yuriy	
Lodhi, Aysha	· ·
Lozovska, Tetyana	.Hooper's Pharmacy
Luong, Duy	.Shoppers Drug Mart
Maalawy, Moheb	•
Maghera, Jagjit	
Mah-Allum, Yee-ping	
	Eglinton Churchill Medical Pharmacy
Makar, Nancy	
Morgan, Nabil	
Nonomura, Margaret	
Overland, Jack	
Paggos, Marios	
Panchmatia, Mehul	
	.Meadowvale Professional Centre Pharmacy
Patel, Anil	3
Patel, Devendra	
Patel, Jai	
Patel, Nikki	.Shoppers Drug Mart

Philemon, Maggie Pilkington, Victoria Post, Eric Prajapati, Poonam Qureshi, Tajammal Rajput, Jasbir Ravji, Tarulata Rifai, Reem Saad, Adel Salonga-Abule, Arlene Samonis, Ruta Sarma, Vijay Sidrak, Sameh Simonot, Nancy Singh, Bharpur Tawfik, Olivia Towadros, Adel Ur Rehman, Najeeb Uy-gallardo, Janeth	River Run Pharmasave Eglinton Churchill Medical Pharmacy The Trillium Health Centre Guru Nanak Dev Pharmacentre Shoppers Drug Mart Battleford Pharmacy Inc City Centre Remedy's Rx Shoppers Drug Mart City Centre Remedy's Rx Woodchester IDA Pharmacy The Credit Valley Hospital Guru Nanak Dev Pharmacentre Target Pharmacy King Medical Arts Pharmacy N.K.S. Health The Credit Valley Hospital Van Mills IDA Pharmacy Courtesy IDA Pharmacy Shoppers Drug Mart Medical Pharmacy Costco Pharmacy
Varma, Kalpeshkumar.	Costco Pharmacy
Vora, Adesh	Total Health Pharmacy
Waseem, Ahmad	Shoppers Drug Mart
Yun, Anna	The Trillium Health Centre
MOOSONEE	

Hermogeno, Ofelia.....Northern Pharmacy

MORRISBURG

Bonyun, Sandra Seaway Valley Pharmacy Morrisburg

NAPANEE

Hager, Jason......Gray's IDA Drug Store

McBride, John...Lennox-Addington Count General Hospital

NEPEAN

NEPEAN	
Badawy, Tamer	Medisystem Pharmacy
Bazarjani, Homa	Loblaw Pharmacy
Darras, Ra'ed	Target Pharmacy
Dyyat, Moh'd Yaser	Shoppers Drug Mart
Forbes, Cameron	Queensway-Carleton Hospital
Frankenne, Angela	Loblaw Pharmacy
Gabriel, Sally	Centrepointe Gabriel Drugs
Guest, Michael	Medisystem Pharmacy
Long, Alana	Queensway-Carleton Hospital
MacPherson, George	Barrhaven Pharmacy
Najm, Maya	Loblaw Pharmacy
Rowland, Martin	Queensway-Carleton Hospital
Smulczynska, Agnieszka	Shoppers Drug Mart

NEW LISKEARD

McCaig, Andrew	Findlay's Drug Store
McKnight, Patti	Loblaw Pharmacy

NEWCASTLE

Koo, Joseph	.Shoppers Drug Mart
Wotherspoon, Maari	.Shoppers Drug Mart

, , , , , , , , , , , , , , , , , , , ,	
NEWMARKET	
Gasic, Dragana	Shoppers Drug Mart
Labelle, Julianne	Southlake Regional Health Centre
Li Kwong Ken, Moy	Shoppers Drug Mart
Pick, Bryan	Southlake Regional Health Centre
Singh, Mandeep	Shoppers Drug Mart

NIAGARA FALLS

Boggio, Aaron	Boggio & MacKinnon Pharmacy
Hammond, Frederick	The Greater Niagara General Hospital
Khan, Muhammad	The Greater Niagara General Hospital
Lagace, Tania	Pharma Plus
Paolone, Thomas	Meadows Pharmacy Limited
Schoenhals, Jennifer	Falls Pharmacy Limited

NIAGARA ON THE LAKE

Miller, LoriSimpson's Apothecary Pharmasave

NIPIGON

Dupuis, Jonah.....Rexall

NORTH BAY

Cheverie, Danielle.....Shoppers Drug Mart Dallaire, Kayla North Bay Regional Health Centre Diggles, Mitze.....North Bay Regional Health Centre Euler, PatriciaNorth Bay Regional Health Centre Khalil, Shehab North Bay Guardian Pharmacy Latimer, CurtisShoppers Drug Mart Latimer, Sarah.................Kalvin Brown Pharmasave Mosher, Hannah-Ruth......North Bay Regional Health Centre Prior, VeronicaNorth Bay Regional Health Centre Randall, Lisa......North Bay Regional Health Centre Sermona, MariaLoblaw Pharmacy Woolsey, Matthew.....North Bay Regional Health Centre

Yang, MulinShoppers Drug Mart

NORTH YORK

Abou El Nile, Hatem.....Finch-Weston Medical Pharmacy Cai, Li Rong......North York General Hospital Chan-Lau, Yuen......North York General Hospital Choy, Joyce......North York General Hospital De Leon, Vilma......North York General Hospital Pharmacy Fakoori, FarhangShoppers Drug Mart Filippetto, Nadia.....Shoppers Drug Mart Ghazi Tabatabaie, Leila......North York General Hospital Jackson, Jocelyn North York General Hospital Johnston, KarenSt. John's Rehabilitation Hospital Karmiris, Alexandra.....Shoppers Drug Mart Kwok, Monica Loblaw Pharmacy Lam Shang Leen, Christopher. . . North York General Hospital Pharmacy Lee, Sze......North York General Hospital Massey, Mridula St. John's Rehabilitation Hospital Salgado- Corpuz, Mary North York General Hospital Shi, Mei North York General Hospital Soroka, Yevgeniya Shoppers Drug Mart Tadros, Sylvia......Shoppers Drug Mart

OAKVILLE

Ali, Ahmed Target Pharmacy Bebawy, Adel.....Queen's Drug Mart Conroy, Catherine.....Specialty Prescription Services De Rango, Fabio. Shoppers Drug Mart Depcinski, Tatyana......Halton Healthcare Services Gouda, MichaelShoppers Drug Mart Jones, Andrea......Halton Healthcare Services Kamel, Christine.....Total Health Pharmacy Moreau-Vailloo, Mahalia Halton Healthcare Services Rae, Kimberly Specialty Prescription Services Saghir, Rania Shoppers Drug Mart Salib, MagdaHalton Healthcare Services Sandhu, Kanwardip Shoppers Drug Mart Sourial, Emad Oak Park Community Pharmacy White, Grace......Halton Healthcare Services

OHSWEKEN

Corner, Kimberly Pharmasave

ORANGEVILLE

De Maria, DanielShoppers Drug Mart

ORI FANS

Caron, Guy.....Beausejour Clinic Pharmacy Ltd El-Jaby, Yousra.....Loblaw Pharmacy Khalil, Raafat St. Mary Health Center Pharmacy Trellert, Alison.....Shoppers Drug Mart

OSHAWA

Bick, ErinMedical Pharmacy Chou, JeffreyRexall Pharma Plus Dengre, Neha.....Loblaw Pharmacy Froude, Nancy Lakeridge Health Kwong, Wilson Lakeridge Health Liu, Yang......Costco Pharmacy Murphy, George......Costco Pharmacy Skinner, Linda.....Lakeridge Health Sohaei, Bijan Costco Pharmacy Stock, Anne.....Lakeridge Health Van Rooyen, Wynand......Medical Pharmacy Zahran, ShereenLakeridge Health

OTTAWA

Abdalla, Amira......Shoppers Drug Mart Adelberg, Anna......Remedy's Rx Ali-abdullah, SamiraLoblaw Pharmacy Alnasrawi, Farah Costco Pharmacy Barbalata, Daiana.....Medical Pharmacy Barnes, Mark......Westboro Pharmasave Bedard, Mario The Ottawa Hospital

Bennett, Lindsay The Royal Ottawa Mental Health Centre

Boghossian, Antranik Bell Pharmacy

Buchner, Lisa......The Ottawa Hospital

Changoor, CindyShoppers Drug Mart Crucero, Alpha Rexall Pharma Plus

Dallaire, Sonia......Montfort Hospital D'Angelo Bunch, Tina.....Shoppers Drug Mart Emanuel, Sharon Shoppers Drug Mart Farhat, Lena.....Shoppers Drug Mart

Guest, Michael Medico Dental Pharmacy

Guirquis, Bassem Medical Arts Dispensary of Ottawa (2003) Ltd. Hassan, Zaineb Rexall Pharma Plus

Ibrahim, NajlaaShoppers Drug Mart Issa, AyadShoppers Drug Mart

Joy, Mary The Royal Ottawa Mental Health Centre

Komy, Hany Kilborn Pharmacy

Kozyra, Elizabeth The Royal Ottawa Mental Health Centre

Kuo, Alexander.....The Ottawa Hospital

Lamarche, Marie-PierreCanadian Forces Health Services Centre Ottawa

MacKenzie, JaneThe Ottawa Hospital McDonald, Sandra.....Shoppers Drug Mart Mizrahi, BennyShoppers Drug Mart Naguib, Iman.....Baseline Pharmacy Inc.

Nguyen, PhuongDrugstore Pharmacy Onochie-Roy, Uzoamaka Ottawa Hospital Peterko, Bozena......Classic Care Pharmacy

PRECEPTORS

Salidis, Maher Greenboro Pharmacy	PORT COLBORNE
Schwass, Alison Medical Pharmacy	Matheson, Erin Matheson's Drug Store
Shaheen, Waseem St. Laurent Medical Centre Pharmacy	Saati, Michel - BarsomBoggio Pharmacy Ltd
Shore, Karen Classic Care Pharmacy	Santon, StephenShoppers Drug Mart
Sin, DonaldShoppers Drug Mart	
Skywalker, Luke Blossom Park Pharmacy	PORT HOPE
Spencer, JenniferThe Ottawa Hospital	Ferguson, Kristin Loblaw Pharmacy
Stevens, MarkRexall Pharma Plus	Plummer, DonaldShoppers Drug Mart
Stewart, Carolyn	77
Swetnam, JenniferShoppers Drug Mart	PORT PERRY
Tchen, Meechen	King, ChristieShoppers Drug Mart
Tierney, Sallyanne Bruyere Continuing Care	Tsang, ByronLakeridge Health
Tonon, MatthewNew Edinburgh Pharmacy	
Truong, My-Hanh	PRESCOTT
Varughese, Nisha	Duperron, Elena Shoppers Drug Mart
Wang, HanyuShoppers Drug Mart	Boperron, Elenashoppers Brog Flare
Warren, Natalie	RED LAKE
Watson, MichaelWatson's Pharmacy and Compounding Centre Whittle, JohnDrugstore Pharmacy	Laporte, Bradley
Wilson, LorettaMontfort Hospital	Parete, JeanineRed Lake Pharmacy
vviisori, corectarioritiorit mospital	. d. ede, Sedimie
OWEN SOUND	RENFREW
Benedict, Danielle Medical Pharmacy	Campbell, AnnaRenfrew Victoria Hospital
Vacheresse, MarcGrey Bruce Health Services	Homsma, Ashley
,,,	
PARIS	REXDALE
Hawkins, NatalieNorthville Pharmacy	Nirale, Suhas
PARRY SOUND	RICHMOND HILL
Carter, MiriamWest Parry Sound Health Centre	Abu El Khire, AnisHealth Link Pharmacy
He, BiqiShoppers Drug Mart	Avetissov, Vera
Lane, GordonLane Family Pharmacy	Avinashi, GunjanShoppers Drug Mart
	Blatman, BrianMackenzie Richmond Hill Hospital
PEMBROKE	Chan, Ping-Ching
Bromley, TaraMulvihill Drug Mart	Chan, Wai Yin
Keon, LynnPembroke Regional Hospital Inc	Colella, GiuseppeShoppers Drug Mart
Ouimet, KelliMulvihill Drug Mart	Eftekharinasab, Hossein Loblaw Pharmacy
Tsimiklis, Stavros	Grewal, Neil
Zohr, Andrea	Hanna, Magdy Yashoue Rizkalla .Total Health Pharmacy Ho, Gabrielle
	Kang, MunMackenzie Richmond Hill Hospital
PENETANGUISHENE	Kim, Sun Mackenzie Richmond Hill Hospital
Antenucci, TaniaShoppers Drug Mart	Leong, ShaunCostco Pharmacy
Dubeau, Valerie	Loduca, RichardoShoppers Drug Mart
	Mandlsohn, MarkShoppers Drug Mart
PETAWAWA	Mekhail, Sylvia
Craig, Sean	Mosallam. Tamer
Lui, Kwok LingBase Hospital	Motahari, Massoud
Ouimet, KelliMulvihill Drug Mart	Navabi, Minoo
Rey-McIntyre, Andrew Shoppers Drug Mart	Pezeshki, Dalina
	Ramirez- Hashemi, Pauline Drugstore Pharmacy
PETERBOROUGH	Riad, MiretteLeslie & Major Mac. I.D.A. Pharmacy
Azubuike, MadukweLoblaw Pharmacy	Saad, SamyRichpoint Pharmacy
Bebawy, Deina The Medicine Shoppe	Siwani, Shani-Abbas Uptown Apothecary
Garcha, KiranjeetLoblaw Pharmacy	Tam, MelissaLoblaw Pharmacy
Lovick, Stephen Medical Centre Pharmacy	Wong, SerinaShoppers Drug Mart
Plassery, BijuRexall	
Simmons, Lindsey Peterborough Regional Health Centre	RIDGEWAY
White, Catherine Peterborough Regional Health Centre	Edwards, Donald Boggio & Edwards Ridgeway IDA Pharmacy
PETROLIA	ROCKLAND
McDonald, AnnaLambton Pharmacy	Baker, JoannaShoppers Drug Mart
· ·	Daker, Joanna

SARNIA

Bandiera, Louise......Bluewater Health - Norman Site

Bombardier, Stefanie Bluewater Health - Norman Site

Lund, Sean......Bluewater Pharmacy
Monaghan, Ellen.....Bluewater Health - Norman Site

Laporte, Marcel BMC Pharmacy

Kelch, Richard......Northgate Pharmacy

PAGE 32 ~ WINTER 2013 ~ PHARMACT CONNECTION	PAGE 52	~	WINTER 2015	~	PHARMACY CONNECTION
---	---------	---	-------------	---	---------------------

PICKERING

Hussain, AmirRexall

Shaikh, Nauman.....Rexall

Kalra, Monika Loblaw Pharmacy

Roodbaraki, PoorangShoppers Drug Mart

Suleman, Rahim.....Shoppers Drug Mart

Ting, MilienTarget Pharmacy

SAULT STE MARIE

Casselman, Elizabeth	Market Mall Pharmacy
Cavaliere, Claudio	Merrett's Pharmacy
Davies, Mary	Sault Area Hospital
Desumma, Sebastian	Market Mall Pharmacy
Disano, Joel	Market Mall Pharmacy
Fischer, Olga	Rexall Specialty Pharmacy
Forsyth, Gavin	Sault Area Hospital
Kaupp, Tyler	Medicine Shoppe
MacDonald, John	. The Medicine Shoppe
O'Laney, Marlene	Rexall
Patterson, Paula	Loblaw Pharmacy
Policicchio, Matthew	Wal-Mart Pharmacy
Ross, Susannah	Shoppers Drug Mart
Saleeb, Adel	Central Drug Mart

SCARBOROUGH		
Abdullah, Ahmad	Shoppers Drug Mart	
Amro, Moe		
Babaev, Vadim	Malvern Drug Mart	
Baig, Asad	Shoppers Drug Mart	
Balachandran, Jayashree	Costco Pharmacy	
Baui, Paul	National Pharmacy	
Behiry, Sherif	Cliffside Pharmacy	
Bhanji, Zahir	Remedy's Global Drug Mart Phari	macy
Boudreau, Carrie		,
Cau, Chieng		
Cerovic-Radusinovic, Aleksand		
Chan, Eddy		
Chau, Elizabeth		
Chau, Thomas	Providence Healthcare	
Chin, Donna		
Devaranjan, Anoja		
Dhirani, Akil		
Ebrahimzadeh Ahari, Jamil		
El Komos, Shery		
Farag, Mamdouh	-	
Fares, Ramez		
Fong, Chi	,	
Garabet, Nayre		
Im, Kevin		
lp, Jerry		
Iskander, Maged		
Iskander, Sheri	-	
Kabigting, Ana Marie		
Ko-Takounlao, Betsy		
-	Scarborough Hospital Drug Store - Bir	chmount Campu
Lee, Odelia		'
Li, Brian		
Liu, Man		
Lui, Cecilia		
Malik, Mah-E-Zia		
Mwanza, Leaggy	Shoppers Drug Mart	
Nakhla, Medhat		
Ng, Jenny		
Oommen, Sheema		
Pahlavanmiragha, Nasrin		
Rascu, Maria		
Salib, Ihab	Warden Medical Pharmacy	
Shtein, Viktoria	Shoppers Drug Mart	
	. The Scarborough General Hospita	al
Takopoulos, Ekaterina	Pharmacy	
Tam, Claudia		
Tolentino, Vivian		
Tsao, Liza	-	
	.Boniface Park Medical Pharmacy	
	The Scarborough General Hospita	al
Wong, Victor		
Woo, Ka Kei		
Young, Norma		
Tourig, Indittia	Scarborough Grace Hospital	

SIMCOE

Collver, Tara	Roulston's Pharmacy
Eppel, Constance	Norfolk General Hospital
Holton, Joanne	Roulston's Discount Drugs Ltd
Odumodu, Edward	Clark's Pharmasave Whitehorse Plaza
Snow, Blair	Roulston's Pharmacy
Stephens, Mark	Roulston's Pharmacy

SIOUX LOOKOUT

Link, Sonia Sioux Lookout Meno-Ya-Win Health Centre

SMITHS FALLS

Gagnon, Sandra	Loblaw Pharmacy
Joyner- Castoro, Carrie	Shoppers Drug Mart
Lavoratore, Sara	Smith Falls Community Health Centre, Rideau
	Community Health Services
Saad, Ghiwa	Pharma Plus

SMITHVILLE

ST. CATHARINES

Ahmed, Adnan	.Shoppers Drug Mart	
Awadalla, Amir	.Glenridge Pharmacy	
Elnazir, Linda	.Niagara Health System	
Hindi, Eyad	.Montebello Medical Pharmacy	
Kulkarni, Subuddhi	.Hotel Dieu Shaver Health and Rehabilitation Ce	ntre
Kulkarni, Trupti	.Niagara Health System	
Lagace, Tania	.Niagara Health System	
Patel, Dipikaben	.Loblaw Pharmacy	
Ram, Salini	.Niagara Health System	
Upadhyay, Chirayu	.Wal-Mart Pharmacy	
Tong, Chung	.Medical Pharmacy	
Wiebe, Brendon	.Niagara Health System	

ST. MARYS

ST. THOMAS

Campbell, Sandra	.St. Thomas-Elgin General Hospital
Feenstra, Cheryl	.Shoppers Drug Mart
Fletcher, Kathryn	.St. Thomas-Elgin General Hospital
Hache, Richard	.St. Thomas-Elgin General Hospital
Kolator-Cotnam, Susan	.St. Thomas-Elgin General Hospital

STITTSVILLE

Fairfax, Amanda	Shoppers Drug Mart
Ledas, Jane	Stittsville IDA Pharmacy

STONEY CREEK

Arumugasamy, Srivard	han Supercare Pharmacy Stoney Creek Pharmasave
Carvalho, Lisa	Loblaw Pharmacy
Gayowski, Mark	Pharmasave
Nardini, John	Shoppers Drug Mart

STRATFORD

Adair, Kristy	.Sinclair Pharmacy
Alderdice, Jennifer	.Stratford General Hospital
Davidson, Pamela	.Stratford General Hospital

STRATHROY

Nethercott, Ashley	Shoppers Drug Mart
Vander Gulik, Nicholas	Shoppers Drug Mart

STREETSVILLE

Shalvardjian, Berge	Robinson's IDA Pharmacy
Wong, Cindy	Robinson's IDA Pharmacy

PRECEPTORS

SUDBURY		Chan Christophor	Shappars Drug Mart
	Modinystom Pharmacy	Chan, Christopher Chaudhry, Komal	
Chappell Adam	Health Sciences North - Ramsey Lake Health Centre	Chen, Edward	
Chenard, Jason		Chen, Thomas	
Dabliz, Sami		Chen, Yan	
Krawczuk, Nykolas	Shoppers Drug Mart	Cheung, Michael	
Lad, Kiran	Rexall		Sunnybrook Health Sciences Centre
Matthews, Kristen	Health Sciences North - Ramsey Lake Health Centre	Chow, Douglas	
McDonald, Glen			Sunnybrook Health Sciences Centre
McMahon, Terry		Cifarelli, Cinzia	
Mullen, Scott	,	Damiani, Fabrizio	
Osmars, Kerah	Health Sciences North - Ramsey Lake Health Centre	Delawala, Soebmohmed	·
Paquette, Jean-Robert			Holland Bloorview Kids Rehabilitation Hospita
Simpson, Sean		Dhaliwall, Jatinderjit	·
·	Plaza 69 - Shoppers Drug Mart	Djazayeri, Shabdis	Transplant Outpatient Pharmacy
	•	Do, Michael	Vina Pharmacy
SUNDRIDGE		Durnford, Colin	*
Lee, Norman	Sundridge Pharmacy Ltd		Islington IDA Pharmacy
			Bathurst-Bloor IDA Drug Mart
SUTTON		Farrand, Jeffrey	
Shaveleva, Larissa	Shoppers Drug Mart		Queen Street Mental Health Centre Runnymede Healthcare Centre
		Francis, Baher	
THORNHILL			Dufferin-Finch Pharmacy
Awadalla, Nadine	Main Drug Mart		St. Gabriel Medical Pharmacy
Botros, Dimiana	Pharma Plus	Giancroce, Pauline	
Liberman, David		Girgis Boktor, Amir	College Medical Pharmacy
Mandel, Sandra	11 9	Grewal, Gagandeep	Mount Sinai Hospital
Maurice, Bichoy	•	Gupta, Ashwin	
Yoo, Jion	Allan's Community Pharmacy	Hannaalla, Samer	,
100, Jion	Galleria Priarmacy	Hansra, Manjit	
THORNTON			Toronto East Pharmasave
	Thornton Pharmacy and Health Food Ltd.	Hirmina, Peter	*
Judido, 7 till lette		Hoang, Julie	· · · · · · · · · · · · · · · · · · ·
THUNDER BAY		Hoang, Roselyn	*
Adams, Brenda	"Janzen's Pharmacy		The Hospital For Sick Children
	Thunder Bay Regional Health Sciences Centre		The Toronto General Hospital
Jacobson, Jeffrey	, ,	Hui, Annie	Ambulatory Patient Pharmacy
Krywy, Todd	Shoppers Drug Mart		The Hospital For Sick Children
Luu, Chi		,	Vitality Compounding Pharmacy
McCutchon, Janet			West Park Healthcare Centre
Miele, Anna		Ip, Robert Siu Lin	
· ·	Thunder Bay Regional Health Sciences Centre	Jaffer, Akeel	Remedy's Rx Eglinton Bayview Pharmacy
Riutta, Christopher	· · · · ·	Jaffer, Imatiaz	
Winter, Allan	· · · · ·		St. Joseph's Health Centre
vviited, / widit		Javaid, Suhail	
TILBURY		Jeyaraj, Balagowri	
Gerges, John	Mill St. Pharmacy	Kakani, Padma	Shoppers Drug Mart
Hennessey, Seana		Kaliy, Olesya	Shoppers Drug Mart
		Kam, Sarah	
TIMMINS			Kassel's Pharmacy Limited
Larocque, Lee-Anne	Timmins And District Hospital	Khatri, Yamu	
Torrens, Natalie	Timmins And District Hospital	Kim, Michelle Kim, Susan	
		Knight, Robyn	
TORONTO		Kong, Josephine	
Abdel Maseh, Nagib		Kue, Kin	
Agada, Luke		Lacsamana, Jason	Sunnybrook Health Sciences Centre
Ahmed, Mohamed	,	Lai, Jane	One Community Pharmacy Inc.
Allaham Hanan		•	Toronto East General Hospital
Allahham, Hanan	Pharmasave Ambulatory Patient Pharmacy	Lee, Kyoung-hee	· ·
Bautista, Adriano		Lee, Nai-Yuen	The state of the s
Bawa, Sameet		Leung, Jennifer	
	The Hospital For Sick Children		Sunnybrook Health Sciences Centre
Bharaj, Rupinder	·	Li, Wilson	Shoppers Drug Mart Toronto East General Hospital
	The Hospital For Sick Children	Liu, Cheng-Cha	
	The Princess Margaret Hospital		The Toronto General Hospital
Brittain, Cherry	Shoppers Drug Mart	Lorestani, Shohreh	·
Brun, Rita	Toronto East General Hospital	Lu, Wei	
	· ·	LU, VVCI	vvai-iriai t Filai IIIacy

ytwyn-Nobili, Elizabeth	Shoppers Drug Mart	Wong, Kam Ying	Wal-Mart Pharmacy
Mandlsohn, Jeffery		Wong, King	
Manickavasagar, Nitharsini			Toronto Manning Drug Mart
Manshouri, Ali	, ,	5 5	University Health Network
Mansoubi, Abdoulnaser	11 3	Wu, Wai-Yan	-
	Dalecliff Medical Pharmacy	Xu, Heng	
9	Queen Street Mental Health Centre	Yamamoto, Misaki	
Marinkovic, Miodrag	· · · · · · · · · · · · · · · · · · ·	Yeganegi, Kamal	
Mehawed, Merry		Yeh, Walter	•
	St. Joseph's Health Centre Pharmacy	Yip, Paul	
	Lakefront Medical Pharmacy	Yiu, Philip	
	The Hospital For Sick Children	Yousef, Aziz	
	· · · · · · · · · · · · · · · · · · ·		Eglinton Medical Pharmacy
Morgan, Faddy			,
Morkos, David	,	Yurchuk, Daniel	
Nahidi, Maral		Zannella, Sterano	Regional Cancer Centre/Odette Car
Nasralla, Pierre	* *	7	Centre Pharmacy
Nazmeen, Mausum	· · · · · · · · · · · · · · · · · · ·	Zervas, John	Shoppers Simply Pharmacy
	Runnymede Healthcare Centre		
Nencheva, Nadya	·	UNIONVILLE	
	Wellcare College Pharmacy	Chan, Suvenna	Shoppers Drug Mart
Ng, Peggy	Shoppers Drug Mart		
Nhan, Jonathan		UXBRIDGE	
Pakbaz, Parisa	Shoppers Drug Mart	Rambe, Eni	Wal-Mart Pharmacy
Panakkal, Silvie	Sunnybrook Health Sciences Centre	. GIIIDC, EIII	
Pandya, Hitesh	Shoppers Drug Mart	VAL CARON	
Papastergiou, John	Shoppers Drug Mart		VIE - D
Parchment-Pinto, Wayna		Bignucolo, Robert	,
Parekh, Rupal	l l	Filo, Michelle	
Patel, Darshana	Rexall Pharma Plus	Jolicoeur, Caroline	Val Est Pharmacy
	Princess Margaret Hospital Outpatient Pharmacy		
Phillips, George	3 ' ' '	VANIER	
	West Park Healthcare Centre	Fisher, Steven	Vanier Pharmacy
	Ambulatory Patient Pharmacy	Ofori-Nyako, Sheila	Drugstore Pharmacy
Raco, Ann-Maria	,	ŕ	,
Ramzy, Ramy	l l	VAUGHAN	
	McKesson Specialty Prescription Services	Kahlon, Shaminder	Shoppors Drug Mart
Remtulla, Nadeem		Meshreki, Mary	
	The Hospital For Sick Children		
		Shams, John	
Rivera, Angeline	·	Simonian, Vartegez	Snoppers Drug Mart
	Care and Health Pharmacy	MIDGII	
Rowntree, Candice		VIRGIL	
Rubbani, Ghulam	3	Dyck, Julie	
Rubin, Bonita		Ritter, Sandra	Simpson's Pharmasave
	Woodgreen Discount Drugs		
Savage, Mark		WALKERTON	
	St. Joseph's Health Centre	Fullerton Ryan	Brown's Guardian Pharmacy
	The Salvation Army Grace Hospital	, , , , , , , , , , , , , , , , , , , ,	,
Siddiqui, Mansur	Wal-Mart Pharmacy	WALLACEBURG	
Simon, Mary	GeriatRx Pharmacy)A/ A4 . DI
Singh, Parmanand	Target Pharmacy	Nzekwe, Charles Chimuanya	vval-Mart Pharmacy
Snowdon, James	Snowdon Pharmacy	WATEREARD	
	The Toronto Western Hospital	WATERFORD	
Sookram, Carol	Runnymede Healthcare Centre	Sloot, Robert	Pharma Plus
Sourial, Safwat	,		
	Shoppers Simply Pharmacy	WATERLOO	
Гаn, Kenny		Abu Mazen, Usama	Target Pharmacv
	The Toronto General Hospital	Anand, Veneta	
	Sunnybrook Health Sciences Centre		Westmount Place Pharmacy
erzaghi, Maria			Student Health Pharmacy
homas, Koshy		1 atc, Ni ai	Stodent Fledith Flidiflidey
	Queen Street Mental Health Centre	WATFORD	
homas, Suresh		Yadav, Nilesh	McLaren Pharmacy
•	The Toronto General Hospital		
	Lawrence Medical Pharmacy	WEBBWOOD	
ran, Chan		Lagrandeur, Rebecca	North Shore Pharmacy Services
	Princess Margaret Hospital Outpatient Pharmacy	J	
	Clinia Diagrama au	WELLAND	
	Clinic Pharmacy		
Tsiopanas, Patricia	The Hospital For Sick Children	M I : I	CI D 14
「siopanas, Patricia Jttamchandani, Jaya		Muhic, Joanna	
「siopanas, Patricia Jttamchandani, Jaya /idotto, Stephanie	The Hospital For Sick Children Sunnybrook Health Sciences Centre	Okamura, Evelyn	Welland Medical Pharmacy Ltd
「siopanas, Patricia	The Hospital For Sick ChildrenSunnybrook Health Sciences CentreShoppers Drug Mart	Okamura, Evelyn	Welland Medical Pharmacy Ltd Welland County General Hospital
Fsiopanas, Patricia Jttamchandani, Jaya Vidotto, Stephanie Walton, James Watpool, Karen	The Hospital For Sick ChildrenSunnybrook Health Sciences CentreShoppers Drug MartShoppers Drug Mart	Okamura, Evelyn	Welland Medical Pharmacy Ltd Welland County General Hospital
Fsiopanas, Patricia Jttamchandani, Jaya Vidotto, Stephanie Walton, James Watpool, Karen	The Hospital For Sick ChildrenSunnybrook Health Sciences CentreShoppers Drug MartShoppers Drug MartPrincess Margaret Hospital Outpatient Pharmacy	Okamura, Evelyn	Welland Medical Pharmacy Ltd Welland County General Hospital Loblaw Pharmacy

WEST HILL

Jina, Hanif Shoppers Drug Mart

WESTON

Chong, Arlene	.Humber River Regional Hospital
Forgetta, Janet	.Humber River Regional Hospital
Hassan, Farhana	.Shoppers Drug Mart
Lee, Wai	.Humber River Regional Hospital
Soo, Melissa	.Humber River Regional Hospital

WHITBY

Alizadeh, Mehrdad	Ontario Shores Centre for Mental Health Sciences.
Bansal, Sandeep	Shoppers Drug Mart
Brook-Allred, Nicole	Ontario Shores Centre for Mental Health Sciences.
Cairns, Lisa	Ontario Shores Centre for Mental Health Sciences.
Elnazir, Nancy	Total Health Pharmacy
Farooq, Muhammad	Shoppers Drug Mart
Ham, Linda	Shoppers Drug Mart
Jacoub, Phieby	Whitby Medical Pharmacy
Jejna, Melinda	Ontario Shores Centre for Mental Health Sciences.
Razi, Parnia	Ontario Shores Centre for Mental Health Sciences.
Rule, Colin	Shoppers Drug Mart

WILLOWDALE

El-arif, Essam	Fairview Pharmacy
Ghattas, Nermin	IDA Pleasant View Pharmacy
Jabri, Talal	Shoppers Drug Mart
Law, Faye	Shoppers Drug Mart
Lin, Yong	Shoppers Drug Mart
McMullen, Bethany.	Shoppers Drug Mart
Nam, Hyun	Shoppers Drug Mart
Yang-Kim, Clara	Shoppers Drug Mart

WINCHESTER

WINDSOR

Ahmad, Baker	Shoppers Drug Mart
Alam, Intekhab	Shoppers Drug Mart
Aslam, Nadeem	Sure Health Pharmacy
Braccio, Elisa	
Cappellino, Frank	Remedy'sRx
Chang, Robin	Provincial Pharmacy
D'angelo, Rocco	Royal Windsor Pharmacy
Daoud, George	Medical Centre Pharmacy
Dawood, John	Windsor River Pharmacy
Deslippe, Dawn	Windsor Regional Hospital - Metropolitan Campus
Devlin, John	Windsor Regional Hospital - Metropolitan Campus
Di Pietro, Sebastiano	Shoppers Drug Mart
Drouillard, Kellie-Ann	Windsor Regional Hospital - Metropolitan Campus
Dumo, Peter	Novacare Pharmacy
Duronio, Antoinette	Windsor Regional Hospital
Eltoum, Ziad	Shoppers Drug Mart
Garant, Justin	The Drive Pharmacy
Haluk-McMahon, Charlene	Windsor Regional Hospital - Metropolitan Campus
Hissy, Ziad	. Forest Glade Pharmacy
Houle, Karrie	Costco Pharmacy
Kowalik, Ewa	Windsor Regional Cancer Centre
Kummer, Theodore	Shoppers Drug Mart
Nadeau, Lynn	Windsor Regional Hospital
Payne, John	Provincial Pharmacy
Robinson, Linda	Windsor Regional Hospital - Metropolitan Campus
Root, Dana	Windsor Regional Cancer Centre
Rublik, Angel	Windsor Regional Hospital
Staruch, Andrea	Shoppers Drug Mart
Toor, Jasjit	Shoppers Drug Mart
Vella, Francesco	Olde Walkerville Pharmacy
Vereecke, Brigette	Shoppers Drug Mart
Yee, Richard	. Yee Pharmacy Limited

WINGHAM

Chang, Peter.....Wingham And District Hospital

WOODBRIDGE

Bekhit, Andrew	.Costco Pharmacy
Bhatia, Gautam	.Weston Pharmacare
Daneshkhah, Saman	.Costco Pharmacy
Daoud, Fiby	.Costco Pharmacy
Khatoon, Saima	.Wal-Mart Pharmacy
Latif, Imran	.Costco Pharmacy
Lau, Ying	.Costco Pharmacy
Lawrence, James	.Pulse Rx LTC Pharmacy
Omozusi, Ogieriakhi	.Shoppers Drug Mart
Raphael, Mona	.Henderson's Woodbridge Medical Pharmacy
Valela, Anna	.Rexall Pharma Plus
Wong, Terence	.Shoppers Drug Mart

WOODSTOCK

Andrecyk, Stacey	Shoppers Drug Mart
Menezes, Sheila	The Dispensary
Payne, Catherine	Woodstock General Hospital
Reid, Jennifer	Shoppers Drug Mart
Rossi, Francesca	Woodstock General Hospital
Silverthorne, Elizabeth	Shoppers Drug Mart
Tuan, Lee	All About Health Remedy's Rx

CONTINUING EDUCATION (CE)

This list of continuing education activities is provided as a courtesy to members. The Ontario College of Pharmacists does not necessarily endorse the CE activities on this list.

For information on local live CE events in your area you may wish to contact your Regional CE coordinator (list available on the OCP website).

Visit www.ocpinfo.com for an up-to-date list of Continuing Education.

LIVE EVENTS AND CONFERENCES

February 24 or March 9, 2015 (Toronto, ON)
Methadone and Opioid Addiction – Student Education Program

Ontario Pharmacy Association

Contact: https://www.opatoday.com/professional/live-courses

February 26, 2015 (Sudbury, ON)
Patient Engagement, Experience and Relations

Ontario Hospital Association

Contact: http://www.oha.com/Education/Pages/education.aspx

February 28, 2015 (Toronto, ON)

Minor Ailments

University of Toronto

Contact: http://cpd.pharmacy.utoronto.ca/programs/minorailments.html

March 12-13, 2015 (Toronto, ON)
Medication Safety for Pharmacy Practice:
Incident Analysis and prospective risk assessment

Institute for Safe Medication Practices Canada Contact: http://www.ismp-canada.org/index.htm

March 20-22, 2015 (Ottawa, ON) International Meeting on Indigenous Child Health

Canadian Paediatric Society

Contact: http://www.cps.ca/en/imich

March 21-22, 2015 (Part 1) April 25-26, 2015 (Part 2) (Ottawa, ON) Introductory Psychopharmacology for Clinicians

University of Toronto

Contact: http://cpd.pharmacy.utoronto.ca/programs/categories/practice-development.html

March 21-22 and April 25-26, 2015 (Toronto, ON)

Medication Therapy Management for Older Adults - CGP Preparation Course

Ontario Pharmacy Association

Contact: https://www.opatoday.com/professional/live-courses

March 27-29, 2015 (Toronto, ON)

Certified Diabetes Educator Preparation Course

Ontario Pharmacy Association

Contact: https://www.opatoday.com/professional/live-courses

March 28, 2015 (Toronto, ON)

Education Program for Immunization Competencies

Canadian Paediatric Society

Contact: http://www.cps.ca/en/epic-pfci

March 29, 2015 to December 5, 2015 (Multiple Dates and Locations)

An Injection Refresher: Flu and Beyond

Ontario Pharmacists Association

Contact: https://www.opatoday.com/professional/live-courses

April 17-19, 2015 (Toronto, ON)

2015 Travel Medicine Review and Update Course

International Society of Travel Medicine

Contact: http://istmsite.membershipsoftware.org/certificateofknowledgerc

April 25, 2015 (Ottawa, ON)

Mise a Jour 2015 - 32th Annual Conference

The Ottawa Hospital
Contact: http://rxinfo.ca

May 6 - 9, 2015 (Toronto, ON)

Primary Care Today - 13th Annual Conference

University of Toronto

Contact: http://www.mycmeupdates.ca/pct/home.html

May 21 - 22, 2015 (Toronto, ON)

Canadian Association for Ambulatory Care (CAAC) Conference

Canadian Association of Ambulatory Care

Contact: http://www.canadianambulatorycare.com/

May 21 - 22, 2015 (Calgary, ALB)

Cochrane Canada Symposium 2015: Reaching New Heights, Measuring Success

Canadian Cochrane Centre

Contact: https://ccnc.cochrane.org/cochrane-canada-symposium-2015-welcome

May 24-28, 2015 (Quebec, QC)

The 14th Conference of the International Society of Travel Medicine

International Society of Travel Medicine

Contact: http://www.istm.org/

May 28, 2015 (Toronto, ON)

Education Program for Immunization Competencies - 2015

The Canadian Paediatric Society

Contact: http://www.cps.ca/en/epic-pfci

May 28-31, 2015 (Ottawa, ON)

Canadian Pharmacists Conference 2015

Co-hosted by the Canadian Pharmacists Association and the Ontario Pharmacists Association Contact: http://www.pharmacists.ca/index.cfm/news-events/events/events/calendar-of-events/canadian-pharmacists-conference-2015/?month=5&year=2015&categoryID=&relatedID

September 16-18, 2015 (Ottawa, ON)

Community Health Centres: Agents of Care, Agents of Change Conference

Canadian Association of Community Health Centres

Contact: http://www.cachc.ca/acac2015

October 16-18, 2015 (Niagara Falls, ON)

Lifelong Learning in Paediatrics

Canadian Paediatric Society
Contact: http://www.cps.ca/en/llp

October 29 – November 1, 2015 (Ottawa, ON)

Canadian Hospice Palliative Care Conference Canadian Hospice Palliative Care Association

Contact: http://conference.chpca.net/

November 25 - 27, 2015 (Toronto, ON)

Thrombosis Management

University of Toronto

Contact: http://cpd.pharmacy.utoronto.ca/programs/thrombosis.html

Multiple dates and locations – contact course providers

Immunizations and Injections training courses:

Ontario Pharmacists Association: https://www.opatoday.com/223957

RxBriefcase, CPS and PHAC http://www.advancingpractice.com/p-68-immunization-competencies-education-program.aspx

Canadian Health Network: http://www.canadianhealthcarenetwork.ca/pharmacists/

Pear Health http://www.pearhealthcare.com/training-injection-training.php

University of Toronto: http://cpd.pharmacy.utoronto.ca/programs/injections.html

Dalhousie University: http://www.dal.ca/faculty/healthprofessions/cpe/programs/live-programs/immunization-andinjectionadministrationtrainingprogram.html

ONLINE LEARNING/ WEBINARS/ BLENDED CE

Centre for Addiction and Mental Health (CAMH)

Online courses with live workshops in subjects including: TEACH: Certificate Program In Intensive Tobacco Cessation Counselling, TEACH Core Course: A Comprehensive Course on Smoking Cessation , ADAT, Buprenorphine-Assisted Treatment of Opioid Dependence: An Online Course for Front-Line Clinicians, Prescribing Opioids for Chronic Pain, Addressing Opioid Challenges and Addiction, Collaborating with Families Affected by Concurrent Disorders, Concurrent Disorders Core, Concurrent Disorders in Primary Care, Fundamentals of Addiction, Fundamentals of Mental Health, Interactions Between Psychiatric Medications and Drugs of Abuse, Legal Issues in Mental Health Care in Ontario, Medications and Drugs of Abuse Interactions in ODT Clients, Motivational Interviewing introduction Course, Recovery-Oriented Approach, Safe and Effective Use of Opioids for Chronic Non-cancer Pain, Youth, Drugs and Mental Health.

Contact: http://www.camh.ca/en/education/about/AZCourses/Pages/default.aspx

Canadian Pharmacists Association (CPhA)

Home Study Online accredited education programs including: ADAPT Patient Care Skills Development. Lab Tests, Medication Review Services, QUIT: Smoking Cessation Program, Diabetes: CANRISK CE. Contact: http://www.pharmacists.ca/index.cfm/education-practice-resources/professional-development/

Canadian Society of Hospital Pharmacists (CSHP)

Online education programs, including Medication Reconciliation, Minimizing the Risk of Contamination in the Oncology Pharmacy Setting and Immunization Competencies Education Program (ICEP).

Contact: http://www.cshp.ca/programs/onlineeducation/index_e.asp

Canadian Healthcare Network

Online CE Lessons for pharmacists and pharmacy technicians. Contact: http://www.canadianhealthcarenetwork.ca/pharmacists/

Continuous Professional Development - University of Toronto, Leslie Dan Faculty of Pharmacy: Infectious

Diseases Online Video Lectures and Slides, Influenza DVD, Canadian Health Care System, Culture and Context, Canadian Pharmacist Skills 1 (CPS1)

Contact: http://cpd.pharmacy.utoronto.ca/

Complimentary from OCP and University of Toronto, Leslie Dan Faculty of Pharmacy: Collaborative Care: Conflict In Inter-Professional Collaboration; Pain: Chronic Non-Cancer Pain; Pharmacists Role: Who Do We Think We Are? The '10 Minute Patient Interview' webcast; Physical Assessment for Pharmacists; There is no "I" in "Team", The Why and How Of Deprescribing.

Contact: http://www.ocpinfo.com/practice-education/continuing-education/listings/pharmacists/

Institute for Safe Medication Practices Canada (ISMP)

Online webinars including: MedRec in Primary Care: Best Practices & Improving Patient Safety. Contact: https://www.ismp-canada.org/education/

Ontario Pharmacists Association (OPA)

Online courses with live workshops in subjects including: Methadone Education Program, Principles of Oncology Treatments and Pharmaceutical Care, Infant Care and Nutrition, Natural Health Products, Infectious Disease – Foundations for Pharmacy, Implementing Smoking Cessation Services in the Pharmacy, From pink eye to athlete's foot: Pharmacists' role in common ailments, Medical directives, Pharmacist Health Coaching – Cardiovascular Program.

Complimentary online courses include: Ontario Drug Benefit blood glucose test strip reimbursement policy: Support tools for pharmacists, Managing Menopause and its Associated Disorders, Contact: http://www.opatoday.com/professional/online-learning

rxBriefcase

Online CE Lessons (Clinical and Collaborative Care series) and the Immunization Competencies Education Program (ICEP).

Contact: http://www.rxbriefcase.com/

Ontario is fortunate to have a dedicated team of regional CE Coordinators, who volunteer their time and effort to facilitate CE events around the province.

OCP extends its sincere appreciation and thanks to each and every member of these teams for their commitment and dedication in giving back to the profession.

Interested in expanding your network and giving back to the profession?

Additional regional CE coordinators and associate coordinators are needed in regions 4 (Pembroke and area), 9 (Lindsay area), 10 (North Bay area), 16 (Niagara area) 17 (Brantford area), 25 (Sault Ste. Marie area), 26 (Thunder Bay area) 27 (Timmins area). A complete list of CE coordinators and regions by town/city is available on our website.

To apply, submit your resume to ckuhn@ocpinfo.com

